idB
stringlengths
19
25
idA
stringlengths
19
25
sentA
stringlengths
24
1.82k
sentB
stringlengths
24
1.43k
type
int64
2
2
words
list
wordsA
list
wordsB
list
keywordsA
list
keywordsB
list
labels
list
probs
list
90144_16_item7_p61_s0
90144_15_item7_p111_s0
The Company continually evaluates the applicability of the guidance for regulated operations and whether its regulatory assets and liabilities are probable of inclusion in future regulated rates by considering factors such as a change in the regulator's approach to setting rates from cost-based ratemaking to another fo...
Sierra Pacific continually evaluates the applicability of the guidance for regulated operations and whether its regulatory assets and liabilities are probable of inclusion in future regulated rates by considering factors such as a change in the regulator's approach to setting rates from cost-based ratemaking to another...
2
[ "<tag1>", "The", "Company", "continually", "evaluates", "the", "applicability", "of", "the", "guidance", "for", "regulated", "operations", "and", "whether", "its", "regulatory", "assets", "and", "liabilities", "are", "probable", "of", "inclusion", "in", "future", ...
[ "The", "Company", "continually", "evaluates", "the", "applicability", "of", "the", "guidance", "for", "regulated", "operations", "and", "whether", "its", "regulatory", "assets", "and", "liabilities", "are", "probable", "of", "inclusion", "in", "future", "regulated",...
[ "Sierra", "Pacific", "continually", "evaluates", "the", "applicability", "of", "the", "guidance", "for", "regulated", "operations", "and", "whether", "its", "regulatory", "assets", "and", "liabilities", "are", "probable", "of", "inclusion", "in", "future", "regulate...
[]
[ "Sierra", "Pacific", "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, ...
90144_16_item7_p61_s1
90144_15_item7_p111_s1
The Company believes the application of the guidance for regulated operations is appropriate and its existing regulatory assets and liabilities are probable of inclusion in future regulated rates.
Sierra Pacific believes the application of the guidance for regulated operations is appropriate and its existing regulatory assets and liabilities are probable of inclusion in future regulated rates.
2
[ "<tag1>", "The", "Company", "believes", "the", "application", "of", "the", "guidance", "for", "regulated", "operations", "is", "appropriate", "and", "its", "existing", "regulatory", "assets", "and", "liabilities", "are", "probable", "of", "inclusion", "in", "futur...
[ "The", "Company", "believes", "the", "application", "of", "the", "guidance", "for", "regulated", "operations", "is", "appropriate", "and", "its", "existing", "regulatory", "assets", "and", "liabilities", "are", "probable", "of", "inclusion", "in", "future", "regul...
[ "Sierra", "Pacific", "believes", "the", "application", "of", "the", "guidance", "for", "regulated", "operations", "is", "appropriate", "and", "its", "existing", "regulatory", "assets", "and", "liabilities", "are", "probable", "of", "inclusion", "in", "future", "re...
[]
[ "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 1, 1, -100, -100, -100, 0, -100, -100, 0, 0, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_16_item7_p62_s3
90144_15_item7_p111_s5
Refer to Note 6 of Notes to Consolidated Financial Statements in Item 8 of this Form 10 - K for additional information regarding the Company's regulatory assets and liabilities.
Refer to Sierra Pacific 's Note 5 of Notes to Consolidated Financial Statements in Item 8 of this Form 10 - K for additional information regarding Sierra Pacific 's regulatory assets and liabilities.
2
[ "<tag1>", "Refer", "to", "Note", "6", "of", "Notes", "to", "Consolidated", "Financial", "Statements", "in", "Item", "8", "of", "this", "Form", "10", "-", "K", "for", "additional", "information", "regarding", "the", "Company", "'s", "regulatory", "assets", "a...
[ "Refer", "to", "Note", "6", "of", "Notes", "to", "Consolidated", "Financial", "Statements", "in", "Item", "8", "of", "this", "Form", "10", "-", "K", "for", "additional", "information", "regarding", "the", "Company", "'s", "regulatory", "assets", "and", "liab...
[ "Refer", "to", "Sierra", "Pacific", "'s", "Note", "5", "of", "Notes", "to", "Consolidated", "Financial", "Statements", "in", "Item", "8", "of", "this", "Form", "10", "-", "K", "for", "additional", "information", "regarding", "Sierra", "Pacific", "'s", "regul...
[]
[ "Sierra", "Pacific", "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, -100, 1, 1, 0, -100, -100, 0, 0, 0,...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
90144_16_item7_p63_s0
90144_15_item7_p112_s0
The Company evaluates long-lived assets for impairment, including property, plant and equipment, when events or changes in circumstances indicate that the carrying value of such assets may not be recoverable or the assets are being held for sale.
Sierra Pacific evaluates long-lived assets for impairment, including property, plant and equipment, when events or changes in circumstances indicate that the carrying value of such assets may not be recoverable or the assets are being held for sale.
2
[ "<tag1>", "The", "Company", "evaluates", "long", "-", "lived", "assets", "for", "impairment", ",", "including", "property", ",", "plant", "and", "equipment", ",", "when", "events", "or", "changes", "in", "circumstances", "indicate", "that", "the", "carrying", ...
[ "The", "Company", "evaluates", "long", "-", "lived", "assets", "for", "impairment", ",", "including", "property", ",", "plant", "and", "equipment", ",", "when", "events", "or", "changes", "in", "circumstances", "indicate", "that", "the", "carrying", "value", "...
[ "Sierra", "Pacific", "evaluates", "long", "-", "lived", "assets", "for", "impairment", ",", "including", "property", ",", "plant", "and", "equipment", ",", "when", "events", "or", "changes", "in", "circumstances", "indicate", "that", "the", "carrying", "value", ...
[]
[ "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
90144_16_item7_p65_s2
90144_15_item7_p114_s2
Any resulting impairment loss is highly dependent on the underlying assumptions and could significantly affect the Company's results of operations.
Any resulting impairment loss is highly dependent on the underlying assumptions and could significantly affect Sierra Pacific 's results of operations.
2
[ "<tag1>", "Any", "resulting", "impairment", "loss", "is", "highly", "dependent", "on", "the", "underlying", "assumptions", "and", "could", "significantly", "affect", "the", "Company", "'s", "results", "of", "operations", ".", "<tag2>", "Any", "resulting", "impairm...
[ "Any", "resulting", "impairment", "loss", "is", "highly", "dependent", "on", "the", "underlying", "assumptions", "and", "could", "significantly", "affect", "the", "Company", "'s", "results", "of", "operations", "." ]
[ "Any", "resulting", "impairment", "loss", "is", "highly", "dependent", "on", "the", "underlying", "assumptions", "and", "could", "significantly", "affect", "Sierra", "Pacific", "'s", "results", "of", "operations", "." ]
[]
[ "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, 0, -100, 0, -100, -100, 0, 0, -100, -100, -100, -100, -100, 0, -100, 1, 1, -100, -100,...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_16_item7_p66_s0
90144_15_item7_p115_s0
In determining the Company's income taxes, management is required to interpret complex income tax laws and regulations, which includes consideration of regulatory implications imposed by the Company's various regulatory jurisdictions.
In determining Sierra Pacific 's income taxes, management is required to interpret complex income tax laws and regulations, which includes consideration of regulatory implications imposed by Sierra Pacific 's various regulatory jurisdictions.
2
[ "<tag1>", "In", "determining", "the", "Company", "'s", "income", "taxes", ",", "management", "is", "required", "to", "interpret", "complex", "income", "tax", "laws", "and", "regulations", ",", "which", "includes", "consideration", "of", "regulatory", "implications...
[ "In", "determining", "the", "Company", "'s", "income", "taxes", ",", "management", "is", "required", "to", "interpret", "complex", "income", "tax", "laws", "and", "regulations", ",", "which", "includes", "consideration", "of", "regulatory", "implications", "impose...
[ "In", "determining", "Sierra", "Pacific", "'s", "income", "taxes", ",", "management", "is", "required", "to", "interpret", "complex", "income", "tax", "laws", "and", "regulations", ",", "which", "includes", "consideration", "of", "regulatory", "implications", "imp...
[]
[ "Sierra", "Pacific", "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, -100, 1, 1, -...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
90144_16_item7_p66_s1
90144_15_item7_p115_s1
The Company's income tax returns are subject to continuous examinations by federal, state and local income tax authorities that may give rise to different interpretations of these complex laws and regulations.
Sierra Pacific 's income tax returns are subject to continuous examinations by federal, state and local income tax authorities that may give rise to different interpretations of these complex laws and regulations.
2
[ "<tag1>", "The", "Company", "'s", "income", "tax", "returns", "are", "subject", "to", "continuous", "examinations", "by", "federal", ",", "state", "and", "local", "income", "tax", "authorities", "that", "may", "give", "rise", "to", "different", "interpretations"...
[ "The", "Company", "'s", "income", "tax", "returns", "are", "subject", "to", "continuous", "examinations", "by", "federal", ",", "state", "and", "local", "income", "tax", "authorities", "that", "may", "give", "rise", "to", "different", "interpretations", "of", ...
[ "Sierra", "Pacific", "'s", "income", "tax", "returns", "are", "subject", "to", "continuous", "examinations", "by", "federal", ",", "state", "and", "local", "income", "tax", "authorities", "that", "may", "give", "rise", "to", "different", "interpretations", "of",...
[]
[ "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 1, 1, -100, 0, -100, -...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
90144_16_item7_p67_s0
90144_15_item7_p115_s3
The Company recognizes the tax benefit from an uncertain tax position only if it is more-likely-than-not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.
Sierra Pacific recognizes the tax benefit from an uncertain tax position only if it is more-likely-than-not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.
2
[ "<tag1>", "The", "Company", "recognizes", "the", "tax", "benefit", "from", "an", "uncertain", "tax", "position", "only", "if", "it", "is", "more", "-", "likely", "-", "than", "-", "not", "that", "the", "tax", "position", "will", "be", "sustained", "on", ...
[ "The", "Company", "recognizes", "the", "tax", "benefit", "from", "an", "uncertain", "tax", "position", "only", "if", "it", "is", "more", "-", "likely", "-", "than", "-", "not", "that", "the", "tax", "position", "will", "be", "sustained", "on", "examination...
[ "Sierra", "Pacific", "recognizes", "the", "tax", "benefit", "from", "an", "uncertain", "tax", "position", "only", "if", "it", "is", "more", "-", "likely", "-", "than", "-", "not", "that", "the", "tax", "position", "will", "be", "sustained", "on", "examinat...
[]
[ "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
90144_16_item7_p67_s2
90144_15_item7_p115_s5
Although the ultimate resolution of the Company's federal, state and local income tax examinations is uncertain, the Company believes it has made adequate provisions for these income tax positions.
Although the ultimate resolution of Sierra Pacific 's federal, state and local income tax examinations is uncertain, Sierra Pacific believes it has made adequate provisions for these income tax positions.
2
[ "<tag1>", "Although", "the", "ultimate", "resolution", "of", "the", "Company", "'s", "federal", ",", "state", "and", "local", "income", "tax", "examinations", "is", "uncertain", ",", "the", "Company", "believes", "it", "has", "made", "adequate", "provisions", ...
[ "Although", "the", "ultimate", "resolution", "of", "the", "Company", "'s", "federal", ",", "state", "and", "local", "income", "tax", "examinations", "is", "uncertain", ",", "the", "Company", "believes", "it", "has", "made", "adequate", "provisions", "for", "th...
[ "Although", "the", "ultimate", "resolution", "of", "Sierra", "Pacific", "'s", "federal", ",", "state", "and", "local", "income", "tax", "examinations", "is", "uncertain", ",", "Sierra", "Pacific", "believes", "it", "has", "made", "adequate", "provisions", "for",...
[]
[ "Sierra", "Pacific", "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, -100, -100, 0, -100, 1, 1...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
90144_16_item7_p67_s5
90144_15_item7_p115_s7
Refer to Note 11 of Notes to Consolidated Financial Statements in Item 8 of this Form 10 K for additional information regarding the Company's income taxes.
Refer to Sierra Pacific 's Note 9 of Notes to Consolidated Financial Statements in Item 8 of this Form 10 K for additional information regarding Sierra Pacific 's income taxes.
2
[ "<tag1>", "Refer", "to", "Note", "11", "of", "Notes", "to", "Consolidated", "Financial", "Statements", "in", "Item", "8", "of", "this", "Form", "10", "K", "for", "additional", "information", "regarding", "the", "Company", "'s", "income", "taxes", ".", "<tag2...
[ "Refer", "to", "Note", "11", "of", "Notes", "to", "Consolidated", "Financial", "Statements", "in", "Item", "8", "of", "this", "Form", "10", "K", "for", "additional", "information", "regarding", "the", "Company", "'s", "income", "taxes", "." ]
[ "Refer", "to", "Sierra", "Pacific", "'s", "Note", "9", "of", "Notes", "to", "Consolidated", "Financial", "Statements", "in", "Item", "8", "of", "this", "Form", "10", "K", "for", "additional", "information", "regarding", "Sierra", "Pacific", "'s", "income", "...
[]
[ "Sierra", "Pacific", "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, 1, 1, -100, -100, -100, 0, 0, -100, -100, -100...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_16_item7_p68_s0
90144_15_item7_p116_s0
Changes in deferred income tax assets and liabilities that are associated with income tax benefits and expense for certain property-related basis differences and other various differences that the Company is required to pass on to its customers are charged or credited directly to a regulatory asset or liability.
Changes in deferred income tax assets and liabilities that are associated with income tax benefits and expense for certain property-related basis differences and other various differences that Sierra Pacific is required to pass on to its customers are charged or credited directly to a regulatory asset or liability.
2
[ "<tag1>", "Changes", "in", "deferred", "income", "tax", "assets", "and", "liabilities", "that", "are", "associated", "with", "income", "tax", "benefits", "and", "expense", "for", "certain", "property", "-", "related", "basis", "differences", "and", "other", "var...
[ "Changes", "in", "deferred", "income", "tax", "assets", "and", "liabilities", "that", "are", "associated", "with", "income", "tax", "benefits", "and", "expense", "for", "certain", "property", "-", "related", "basis", "differences", "and", "other", "various", "di...
[ "Changes", "in", "deferred", "income", "tax", "assets", "and", "liabilities", "that", "are", "associated", "with", "income", "tax", "benefits", "and", "expense", "for", "certain", "property", "-", "related", "basis", "differences", "and", "other", "various", "di...
[]
[ "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
90144_16_item7_p22_s0
90144_15_item7_p14_s0
The Company incurred costs totaling $20 million in 2013 related to the BHE Merger , consisting of amounts payable under NV Energy's change in control policy of $6 million, accelerated vesting and stock compensation under NV Energy's long-term incentive plan of $7 million, investment banker fees of $6 million and legal ...
Sierra Pacific incurred costs totaling $20 million in 2013 related to the BHE Merger, consisting of amounts payable under NV Energy's change in control policy of $6 million, accelerated vesting and stock compensation under NV Energy's long-term incentive plan of $7 million, investment banker fees of $6 million and lega...
2
[ "<tag1>", "The", "Company", "incurred", "costs", "totaling", "$", "20", "million", "in", "2013", "related", "to", "the", "BHE", "Merger", ",", "consisting", "of", "amounts", "payable", "under", "NV", "Energy", "'s", "change", "in", "control", "policy", "of",...
[ "The", "Company", "incurred", "costs", "totaling", "$", "20", "million", "in", "2013", "related", "to", "the", "BHE", "Merger", ",", "consisting", "of", "amounts", "payable", "under", "NV", "Energy", "'s", "change", "in", "control", "policy", "of", "$", "6...
[ "Sierra", "Pacific", "incurred", "costs", "totaling", "$", "20", "million", "in", "2013", "related", "to", "the", "BHE", "Merger", ",", "consisting", "of", "amounts", "payable", "under", "NV", "Energy", "'s", "change", "in", "control", "policy", "of", "$", ...
[]
[ "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, ...
90144_16_item7_p1_s0
90144_15_item7_p1_s0
The following is management's discussion and analysis of certain significant factors that have affected the consolidated financial condition and results of operations of the Company during the periods included herein.
The following is management's discussion and analysis of certain significant factors that have affected the consolidated financial condition and results of operations of Sierra Pacific during the periods included herein.
2
[ "<tag1>", "The", "following", "is", "management", "'s", "discussion", "and", "analysis", "of", "certain", "significant", "factors", "that", "have", "affected", "the", "consolidated", "financial", "condition", "and", "results", "of", "operations", "of", "the", "Com...
[ "The", "following", "is", "management", "'s", "discussion", "and", "analysis", "of", "certain", "significant", "factors", "that", "have", "affected", "the", "consolidated", "financial", "condition", "and", "results", "of", "operations", "of", "the", "Company", "du...
[ "The", "following", "is", "management", "'s", "discussion", "and", "analysis", "of", "certain", "significant", "factors", "that", "have", "affected", "the", "consolidated", "financial", "condition", "and", "results", "of", "operations", "of", "Sierra", "Pacific", ...
[]
[ "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, -100, 0, -10...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
90144_16_item7_p1_s2
90144_15_item7_p1_s2
This discussion should be read in conjunction with the Company's historical Consolidated Financial Statements and Notes to Consolidated Financial Statements in Item 8 of this Form 10-K. The Company's actual results in the future could differ significantly from the historical results.
This discussion should be read in conjunction with Sierra Pacific 's historical Consolidated Financial Statements and Notes to Consolidated Financial Statements in Item 8 of this Form 10 K. Sierra Pacific 's actual results in the future could differ significantly from the historical results.
2
[ "<tag1>", "This", "discussion", "should", "be", "read", "in", "conjunction", "with", "the", "Company", "'s", "historical", "Consolidated", "Financial", "Statements", "and", "Notes", "to", "Consolidated", "Financial", "Statements", "in", "Item", "8", "of", "this", ...
[ "This", "discussion", "should", "be", "read", "in", "conjunction", "with", "the", "Company", "'s", "historical", "Consolidated", "Financial", "Statements", "and", "Notes", "to", "Consolidated", "Financial", "Statements", "in", "Item", "8", "of", "this", "Form", ...
[ "This", "discussion", "should", "be", "read", "in", "conjunction", "with", "Sierra", "Pacific", "'s", "historical", "Consolidated", "Financial", "Statements", "and", "Notes", "to", "Consolidated", "Financial", "Statements", "in", "Item", "8", "of", "this", "Form",...
[]
[ "Sierra", "Pacific", "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
90144_16_item7_p22_s0
90144_15_item7_p22_s0
The Company incurred costs totaling $20 million in 2013 related to the BHE Merger , consisting of amounts payable under NV Energy's change in control policy of $6 million, accelerated vesting and stock compensation under NV Energy's long-term incentive plan of $7 million, investment banker fees of $6 million and legal ...
Sierra Pacific incurred costs totaling $20 million in 2013 related to the BHE Merger, consisting of amounts payable under NV Energy's change in control policy of $6 million, accelerated vesting and stock compensation under NV Energy's long-term incentive plan of $7 million, investment banker fees of $6 million and lega...
2
[ "<tag1>", "The", "Company", "incurred", "costs", "totaling", "$", "20", "million", "in", "2013", "related", "to", "the", "BHE", "Merger", ",", "consisting", "of", "amounts", "payable", "under", "NV", "Energy", "'s", "change", "in", "control", "policy", "of",...
[ "The", "Company", "incurred", "costs", "totaling", "$", "20", "million", "in", "2013", "related", "to", "the", "BHE", "Merger", ",", "consisting", "of", "amounts", "payable", "under", "NV", "Energy", "'s", "change", "in", "control", "policy", "of", "$", "6...
[ "Sierra", "Pacific", "incurred", "costs", "totaling", "$", "20", "million", "in", "2013", "related", "to", "the", "BHE", "Merger", ",", "consisting", "of", "amounts", "payable", "under", "NV", "Energy", "'s", "change", "in", "control", "policy", "of", "$", ...
[]
[ "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, ...
90144_16_item7_p25_s0
90144_15_item7_p25_s0
(1) Refer to Note 7 of Notes to Consolidated Financial Statements in Item 8 of this Form 10 - K for further discussion regarding the Company's credit facility.
(1) Refer to Note 6 of Notes to Consolidated Financial Statements in Item 8 of this Form 10 - K for further discussion regarding Sierra Pacific 's credit facility.
2
[ "<tag1>", "(", "1", ")", "Refer", "to", "Note", "7", "of", "Notes", "to", "Consolidated", "Financial", "Statements", "in", "Item", "8", "of", "this", "Form", "10", "-", "K", "for", "further", "discussion", "regarding", "the", "Company", "'s", "credit", "...
[ "(", "1", ")", "Refer", "to", "Note", "7", "of", "Notes", "to", "Consolidated", "Financial", "Statements", "in", "Item", "8", "of", "this", "Form", "10", "-", "K", "for", "further", "discussion", "regarding", "the", "Company", "'s", "credit", "facility", ...
[ "(", "1", ")", "Refer", "to", "Note", "6", "of", "Notes", "to", "Consolidated", "Financial", "Statements", "in", "Item", "8", "of", "this", "Form", "10", "-", "K", "for", "further", "discussion", "regarding", "Sierra", "Pacific", "'s", "credit", "facility"...
[]
[ "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, 0, 0, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
90144_16_item7_p32_s0
90144_15_item7_p26_s0
Net cash flows from operating activities for the years ended December 31, 2014 and 2013 were $246 million and $226 million , respectively.
Net cash flows from investing activities for the years ended December 31 , 2014 and 2013 were $(186) million and $(139) million , respectively.
2
[ "<tag1>", "Net", "cash", "flows", "from", "operating", "activities", "for", "the", "years", "ended", "December", "31", ",", "2014", "and", "2013", "were", "$", "246", "million", "and", "$", "226", "million", ",", "respectively", ".", "<tag2>", "Net", "cash...
[ "Net", "cash", "flows", "from", "operating", "activities", "for", "the", "years", "ended", "December", "31", ",", "2014", "and", "2013", "were", "$", "246", "million", "and", "$", "226", "million", ",", "respectively", "." ]
[ "Net", "cash", "flows", "from", "investing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2014", "and", "2013", "were", "$", "(", "186", ")", "million", "and", "$", "(", "139", ")", "million", ",", "respectively", "." ]
[]
[ "investing", "186", "139" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, 1, 0, 0, 0, -100, 0, 0, -100, -100, -1...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_16_item7_p34_s0
90144_15_item7_p26_s0
Net cash flows from operating activities for the years ended December 31, 2014 and 2013 were $246 million and $226 million , respectively.
Net cash flows from financing activities for the years ended December 31 , 2014 and 2013 were $(105) million and $(81) million , respectively.
2
[ "<tag1>", "Net", "cash", "flows", "from", "operating", "activities", "for", "the", "years", "ended", "December", "31", ",", "2014", "and", "2013", "were", "$", "246", "million", "and", "$", "226", "million", ",", "respectively", ".", "<tag2>", "Net", "cash...
[ "Net", "cash", "flows", "from", "operating", "activities", "for", "the", "years", "ended", "December", "31", ",", "2014", "and", "2013", "were", "$", "246", "million", "and", "$", "226", "million", ",", "respectively", "." ]
[ "Net", "cash", "flows", "from", "financing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2014", "and", "2013", "were", "$", "(", "105", ")", "million", "and", "$", "(", "81", ")", "million", ",", "respectively", "." ]
[]
[ "financing", "105", "81" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, 0, 0, -100, 1, 0, 0, -100, -100, 0, 0, -100, -100, -100,...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_16_item7_p27_s0
90144_15_item7_p28_s0
Net cash flows from investing activities for the years ended December 31, 2014 and 2013 were $(186) million and $(139) million , respectively.
Net cash flows from operating activities for the years ended December 31 , 2014 and 2013 were $246 million and $226 million , respectively.
2
[ "<tag1>", "Net", "cash", "flows", "from", "investing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2014", "and", "2013", "were", "$", "(", "186", ")", "million", "and", "$", "(", "139", ")", "million", ",", "respectively", ".", ...
[ "Net", "cash", "flows", "from", "investing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2014", "and", "2013", "were", "$", "(", "186", ")", "million", "and", "$", "(", "139", ")", "million", ",", "respectively", "." ]
[ "Net", "cash", "flows", "from", "operating", "activities", "for", "the", "years", "ended", "December", "31", ",", "2014", "and", "2013", "were", "$", "246", "million", "and", "$", "226", "million", ",", "respectively", "." ]
[]
[ "operating" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, 1, -100, -100, -10...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_16_item7_p34_s0
90144_15_item7_p28_s0
Net cash flows from investing activities for the years ended December 31, 2014 and 2013 were $(186) million and $(139) million , respectively.
Net cash flows from financing activities for the years ended December 31 , 2014 and 2013 were $(105) million and $(81) million , respectively.
2
[ "<tag1>", "Net", "cash", "flows", "from", "investing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2014", "and", "2013", "were", "$", "(", "186", ")", "million", "and", "$", "(", "139", ")", "million", ",", "respectively", ".", ...
[ "Net", "cash", "flows", "from", "investing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2014", "and", "2013", "were", "$", "(", "186", ")", "million", "and", "$", "(", "139", ")", "million", ",", "respectively", "." ]
[ "Net", "cash", "flows", "from", "financing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2014", "and", "2013", "were", "$", "(", "105", ")", "million", "and", "$", "(", "81", ")", "million", ",", "respectively", "." ]
[]
[ "financing" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, 1, 0, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
90144_16_item7_p27_s0
90144_15_item7_p30_s0
Net cash flows from financing activities for the years ended December 31, 2014 and 2013 were $(105) million and $(81) million , respectively.
Net cash flows from operating activities for the years ended December 31 , 2014 and 2013 were $246 million and $226 million , respectively.
2
[ "<tag1>", "Net", "cash", "flows", "from", "financing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2014", "and", "2013", "were", "$", "(", "105", ")", "million", "and", "$", "(", "81", ")", "million", ",", "respectively", ".", ...
[ "Net", "cash", "flows", "from", "financing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2014", "and", "2013", "were", "$", "(", "105", ")", "million", "and", "$", "(", "81", ")", "million", ",", "respectively", "." ]
[ "Net", "cash", "flows", "from", "operating", "activities", "for", "the", "years", "ended", "December", "31", ",", "2014", "and", "2013", "were", "$", "246", "million", "and", "$", "226", "million", ",", "respectively", "." ]
[]
[ "operating" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, 1, -100, -100, -10...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_16_item7_p32_s0
90144_15_item7_p30_s0
Net cash flows from financing activities for the years ended December 31, 2014 and 2013 were $(105) million and $(81) million , respectively.
Net cash flows from investing activities for the years ended December 31 , 2014 and 2013 were $(186) million and $(139) million , respectively.
2
[ "<tag1>", "Net", "cash", "flows", "from", "financing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2014", "and", "2013", "were", "$", "(", "105", ")", "million", "and", "$", "(", "81", ")", "million", ",", "respectively", ".", ...
[ "Net", "cash", "flows", "from", "financing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2014", "and", "2013", "were", "$", "(", "105", ")", "million", "and", "$", "(", "81", ")", "million", ",", "respectively", "." ]
[ "Net", "cash", "flows", "from", "investing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2014", "and", "2013", "were", "$", "(", "186", ")", "million", "and", "$", "(", "139", ")", "million", ",", "respectively", "." ]
[]
[ "investing" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, 0, 1, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
90144_16_item7_p35_s0
90144_15_item7_p32_s0
The Company's ability to issue debt is primarily impacted by its financing authority from the PUCN .
Sierra Pacific 's ability to issue debt is primarily impacted by its financing authority from the PUCN.
2
[ "<tag1>", "The", "Company", "'s", "ability", "to", "issue", "debt", "is", "primarily", "impacted", "by", "its", "financing", "authority", "from", "the", "PUCN", ".", "<tag2>", "Sierra", "Pacific", "'s", "ability", "to", "issue", "debt", "is", "primarily", "i...
[ "The", "Company", "'s", "ability", "to", "issue", "debt", "is", "primarily", "impacted", "by", "its", "financing", "authority", "from", "the", "PUCN", "." ]
[ "Sierra", "Pacific", "'s", "ability", "to", "issue", "debt", "is", "primarily", "impacted", "by", "its", "financing", "authority", "from", "the", "PUCN", "." ]
[]
[ "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 1, 1, 0, -100, -100, -100, -100, -100, -100, 0, -100, 0, 0, -100, 0, -100, -100, 0, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_16_item7_p35_s1
90144_15_item7_p32_s1
As of December 31, 2014 , the Company has financing authority from the PUCN consisting of the ability to: (1) issue additional long-term debt securities of up to $350 million; (2) refinance up to $348 million of long-term debt securities; and (3) maintain a revolving credit facility of up to $600 million.
As of December 31 , 2015 , Sierra Pacific has financing authority from the PUCN consisting of the ability to: (1) issue additional long-term debt securities of up to $350 million; (2) refinance up to $348 million of long-term debt securities; and (3) maintain a revolving credit facility of up to $600 million.
2
[ "<tag1>", "As", "of", "December", "31", ",", "2014", ",", "the", "Company", "has", "financing", "authority", "from", "the", "PUCN", "consisting", "of", "the", "ability", "to", ":", "(", "1", ")", "issue", "additional", "long", "-", "term", "debt", "secur...
[ "As", "of", "December", "31", ",", "2014", ",", "the", "Company", "has", "financing", "authority", "from", "the", "PUCN", "consisting", "of", "the", "ability", "to", ":", "(", "1", ")", "issue", "additional", "long", "-", "term", "debt", "securities", "o...
[ "As", "of", "December", "31", ",", "2015", ",", "Sierra", "Pacific", "has", "financing", "authority", "from", "the", "PUCN", "consisting", "of", "the", "ability", "to", ":", "(", "1", ")", "issue", "additional", "long", "-", "term", "debt", "securities", ...
[]
[ "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, ...
90144_16_item7_p35_s4
90144_15_item7_p32_s4
However, if the Company's senior secured debt ratings fall below investment grade by either Moody's Investor Service or Standard Poor's, the Company would be subject to limitations under these covenants.
However, if Sierra Pacific 's senior secured debt ratings fall below investment grade by either Moody's Investor Service or Standard Poor's, Sierra Pacific would be subject to limitations under these covenants.
2
[ "<tag1>", "However", ",", "if", "the", "Company", "'s", "senior", "secured", "debt", "ratings", "fall", "below", "investment", "grade", "by", "either", "Moody", "'s", "Investor", "Service", "or", "Standard", "Poor", "'s", ",", "the", "Company", "would", "be"...
[ "However", ",", "if", "the", "Company", "'s", "senior", "secured", "debt", "ratings", "fall", "below", "investment", "grade", "by", "either", "Moody", "'s", "Investor", "Service", "or", "Standard", "Poor", "'s", ",", "the", "Company", "would", "be", "subject...
[ "However", ",", "if", "Sierra", "Pacific", "'s", "senior", "secured", "debt", "ratings", "fall", "below", "investment", "grade", "by", "either", "Moody", "'s", "Investor", "Service", "or", "Standard", "Poor", "'s", ",", "Sierra", "Pacific", "would", "be", "s...
[]
[ "Sierra", "Pacific", "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
90144_16_item7_p36_s0
90144_15_item7_p33_s0
To the extent the Company has the ability to issue debt under the most restrictive covenants in its financing agreements and has financing authority to do so from the PUCN , the Company's ability to issue secured debt is limited by the amount of bondable property or retired bonds that can be used to issue debt under th...
To the extent Sierra Pacific has the ability to issue debt under the most restrictive covenants in its financing agreements and has financing authority to do so from the PUCN, Sierra Pacific 's ability to issue secured debt is limited by the amount of bondable property or retired bonds that can be used to issue debt un...
2
[ "<tag1>", "To", "the", "extent", "the", "Company", "has", "the", "ability", "to", "issue", "debt", "under", "the", "most", "restrictive", "covenants", "in", "its", "financing", "agreements", "and", "has", "financing", "authority", "to", "do", "so", "from", "...
[ "To", "the", "extent", "the", "Company", "has", "the", "ability", "to", "issue", "debt", "under", "the", "most", "restrictive", "covenants", "in", "its", "financing", "agreements", "and", "has", "financing", "authority", "to", "do", "so", "from", "the", "PUC...
[ "To", "the", "extent", "Sierra", "Pacific", "has", "the", "ability", "to", "issue", "debt", "under", "the", "most", "restrictive", "covenants", "in", "its", "financing", "agreements", "and", "has", "financing", "authority", "to", "do", "so", "from", "the", "...
[]
[ "Sierra", "Pacific", "Sierra", "Pacific", "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, ...
90144_16_item7_p36_s1
90144_15_item7_p33_s1
The Company's indenture creates a lien on substantially all of the Company's properties in Nevada.
Sierra Pacific 's indenture creates a lien on substantially all of Sierra Pacific 's properties in Nevada.
2
[ "<tag1>", "The", "Company", "'s", "indenture", "creates", "a", "lien", "on", "substantially", "all", "of", "the", "Company", "'s", "properties", "in", "Nevada", ".", "<tag2>", "Sierra", "Pacific", "'s", "indenture", "creates", "a", "lien", "on", "substantially...
[ "The", "Company", "'s", "indenture", "creates", "a", "lien", "on", "substantially", "all", "of", "the", "Company", "'s", "properties", "in", "Nevada", "." ]
[ "Sierra", "Pacific", "'s", "indenture", "creates", "a", "lien", "on", "substantially", "all", "of", "Sierra", "Pacific", "'s", "properties", "in", "Nevada", "." ]
[]
[ "Sierra", "Pacific", "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 1, 1, 0, 0, 0, 0, -100, 0, 0, -100, 0, 1, 1, 0, 0, 0, 0, 0, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_16_item7_p36_s3
90144_15_item7_p33_s3
The Company had the capacity to issue $900 million of additional general and refunding mortgage securities as of December 31, 2014 determined on the basis of 70% of net utility property additions.
Sierra Pacific had the capacity to issue $1.1 billion of additional general and refunding mortgage securities as of December 31 , 2015 determined on the basis of 70% of net utility property additions.
2
[ "<tag1>", "The", "Company", "had", "the", "capacity", "to", "issue", "$", "900", "million", "of", "additional", "general", "and", "refunding", "mortgage", "securities", "as", "of", "December", "31", ",", "2014", "determined", "on", "the", "basis", "of", "70"...
[ "The", "Company", "had", "the", "capacity", "to", "issue", "$", "900", "million", "of", "additional", "general", "and", "refunding", "mortgage", "securities", "as", "of", "December", "31", ",", "2014", "determined", "on", "the", "basis", "of", "70", "%", "...
[ "Sierra", "Pacific", "had", "the", "capacity", "to", "issue", "$", "1.1", "billion", "of", "additional", "general", "and", "refunding", "mortgage", "securities", "as", "of", "December", "31", ",", "2015", "determined", "on", "the", "basis", "of", "70", "%", ...
[]
[ "Sierra", "Pacific", "1.1", "billion" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 1, 1, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
90144_16_item7_p37_s0
90144_15_item7_p33_s6
The Company also has the ability to release property from the lien of the Company's indenture on the basis of net property additions, cash or retired bonds.
Sierra Pacific also has the ability to release property from the lien of Sierra Pacific 's indenture on the basis of net property additions, cash or retired bonds.
2
[ "<tag1>", "The", "Company", "also", "has", "the", "ability", "to", "release", "property", "from", "the", "lien", "of", "the", "Company", "'s", "indenture", "on", "the", "basis", "of", "net", "property", "additions", ",", "cash", "or", "retired", "bonds", "...
[ "The", "Company", "also", "has", "the", "ability", "to", "release", "property", "from", "the", "lien", "of", "the", "Company", "'s", "indenture", "on", "the", "basis", "of", "net", "property", "additions", ",", "cash", "or", "retired", "bonds", "." ]
[ "Sierra", "Pacific", "also", "has", "the", "ability", "to", "release", "property", "from", "the", "lien", "of", "Sierra", "Pacific", "'s", "indenture", "on", "the", "basis", "of", "net", "property", "additions", ",", "cash", "or", "retired", "bonds", "." ]
[]
[ "Sierra", "Pacific", "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 1, 1, 0, -100, -100, -100, 0, -100, 0, 0, -1...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_16_item7_p37_s1
90144_15_item7_p33_s7
To the extent the Company releases property from the lien of the Company's indenture, it will reduce the amount of securities issuable under the indenture.
To the extent Sierra Pacific releases property from the lien of Sierra Pacific 's indenture, it will reduce the amount of securities issuable under the indenture.
2
[ "<tag1>", "To", "the", "extent", "the", "Company", "releases", "property", "from", "the", "lien", "of", "the", "Company", "'s", "indenture", ",", "it", "will", "reduce", "the", "amount", "of", "securities", "issuable", "under", "the", "indenture", ".", "<tag...
[ "To", "the", "extent", "the", "Company", "releases", "property", "from", "the", "lien", "of", "the", "Company", "'s", "indenture", ",", "it", "will", "reduce", "the", "amount", "of", "securities", "issuable", "under", "the", "indenture", "." ]
[ "To", "the", "extent", "Sierra", "Pacific", "releases", "property", "from", "the", "lien", "of", "Sierra", "Pacific", "'s", "indenture", ",", "it", "will", "reduce", "the", "amount", "of", "securities", "issuable", "under", "the", "indenture", "." ]
[]
[ "Sierra", "Pacific", "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, 0, -100, 1, 1, -100, 0, -100, 0, 0, -100, 1, 1, 0, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_16_item7_p42_s0
90144_15_item7_p37_s0
The Company has contractual cash obligations that may affect its consolidated financial condition.
Sierra Pacific has contractual cash obligations that may affect its consolidated financial condition.
2
[ "<tag1>", "The", "Company", "has", "contractual", "cash", "obligations", "that", "may", "affect", "its", "consolidated", "financial", "condition", ".", "<tag2>", "Sierra", "Pacific", "has", "contractual", "cash", "obligations", "that", "may", "affect", "its", "con...
[ "The", "Company", "has", "contractual", "cash", "obligations", "that", "may", "affect", "its", "consolidated", "financial", "condition", "." ]
[ "Sierra", "Pacific", "has", "contractual", "cash", "obligations", "that", "may", "affect", "its", "consolidated", "financial", "condition", "." ]
[]
[ "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 1, 1, -100, 0, 0, -100, -100, -100, -100, -100, 0, 0, 0, 0, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_16_item7_p43_s1
90144_15_item7_p38_s0
(1) Not reflected on the Consolidated Balance Sheets.
(2) Interest is not reflected on the Consolidated Balance Sheets.
2
[ "<tag1>", "(", "1", ")", "Not", "reflected", "on", "the", "Consolidated", "Balance", "Sheets", ".", "<tag2>", "(", "2", ")", "Interest", "is", "not", "reflected", "on", "the", "Consolidated", "Balance", "Sheets", ".", "<tag3>" ]
[ "(", "1", ")", "Not", "reflected", "on", "the", "Consolidated", "Balance", "Sheets", "." ]
[ "(", "2", ")", "Interest", "is", "not", "reflected", "on", "the", "Consolidated", "Balance", "Sheets", "." ]
[]
[ "Interest" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, 0, -100, 1, -100, -100, -100, 0, -100, -100, 0, -100, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_16_item7_p43_s0
90144_15_item7_p38_s1
(2) Interest is not reflected on the Consolidated Balance Sheets.
(1) Not reflected on the Consolidated Balance Sheets.
2
[ "<tag1>", "(", "2", ")", "Interest", "is", "not", "reflected", "on", "the", "Consolidated", "Balance", "Sheets", ".", "<tag2>", "(", "1", ")", "Not", "reflected", "on", "the", "Consolidated", "Balance", "Sheets", ".", "<tag3>" ]
[ "(", "2", ")", "Interest", "is", "not", "reflected", "on", "the", "Consolidated", "Balance", "Sheets", "." ]
[ "(", "1", ")", "Not", "reflected", "on", "the", "Consolidated", "Balance", "Sheets", "." ]
[]
[]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_16_item7_p44_s0
90144_15_item7_p39_s0
The Company has other types of commitments that arise primarily from unused lines of credit, letters of credit or relate to construction and other development costs (Liquidity and Capital Resources included within this Item 7 and Note 7 ) and uncertain tax positions (Note 11 ), which have not been included in the above...
Sierra Pacific has other types of commitments that arise primarily from unused lines of credit, letters of credit or relate to construction and other development costs (Liquidity and Capital Resources included within this Item 7 and Note 6 ) and uncertain tax positions (Note 9 ), which have not been included in the abo...
2
[ "<tag1>", "The", "Company", "has", "other", "types", "of", "commitments", "that", "arise", "primarily", "from", "unused", "lines", "of", "credit", ",", "letters", "of", "credit", "or", "relate", "to", "construction", "and", "other", "development", "costs", "("...
[ "The", "Company", "has", "other", "types", "of", "commitments", "that", "arise", "primarily", "from", "unused", "lines", "of", "credit", ",", "letters", "of", "credit", "or", "relate", "to", "construction", "and", "other", "development", "costs", "(", "Liquidi...
[ "Sierra", "Pacific", "has", "other", "types", "of", "commitments", "that", "arise", "primarily", "from", "unused", "lines", "of", "credit", ",", "letters", "of", "credit", "or", "relate", "to", "construction", "and", "other", "development", "costs", "(", "Liqu...
[]
[ "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, ...
90144_16_item7_p45_s0
90144_15_item7_p40_s0
The Company is subject to comprehensive regulation.
Sierra Pacific is subject to comprehensive regulation.
2
[ "<tag1>", "The", "Company", "is", "subject", "to", "comprehensive", "regulation", ".", "<tag2>", "Sierra", "Pacific", "is", "subject", "to", "comprehensive", "regulation", ".", "<tag3>" ]
[ "The", "Company", "is", "subject", "to", "comprehensive", "regulation", "." ]
[ "Sierra", "Pacific", "is", "subject", "to", "comprehensive", "regulation", "." ]
[]
[ "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -1, 1, 1, 0, 0, 0, 0, 0, 0, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_16_item7_p4_s0
90144_15_item7_p4_s0
Operating revenue; cost of fuel, energy and capacity; and natural gas purchased for resale are key drivers of the Company's results of operations as they encompass retail and wholesale electricity and natural gas revenue and the direct costs associated with providing electricity and natural gas to customers.
Operating revenue; cost of fuel, energy and capacity; and natural gas purchased for resale are key drivers of Sierra Pacific 's results of operations as they encompass retail and wholesale electricity and natural gas revenue and the direct costs associated with providing electricity and natural gas to customers.
2
[ "<tag1>", "Operating", "revenue", ";", "cost", "of", "fuel", ",", "energy", "and", "capacity", ";", "and", "natural", "gas", "purchased", "for", "resale", "are", "key", "drivers", "of", "the", "Company", "'s", "results", "of", "operations", "as", "they", "...
[ "Operating", "revenue", ";", "cost", "of", "fuel", ",", "energy", "and", "capacity", ";", "and", "natural", "gas", "purchased", "for", "resale", "are", "key", "drivers", "of", "the", "Company", "'s", "results", "of", "operations", "as", "they", "encompass", ...
[ "Operating", "revenue", ";", "cost", "of", "fuel", ",", "energy", "and", "capacity", ";", "and", "natural", "gas", "purchased", "for", "resale", "are", "key", "drivers", "of", "Sierra", "Pacific", "'s", "results", "of", "operations", "as", "they", "encompass...
[]
[ "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
90144_16_item7_p4_s1
90144_15_item7_p4_s1
The Company believes that a discussion of gross margin, representing operating revenue less cost of fuel, energy and capacity and natural gas purchased for resale, is therefore meaningful.
Sierra Pacific believes that a discussion of gross margin, representing operating revenue less cost of fuel, energy and capacity and natural gas purchased for resale, is therefore meaningful.
2
[ "<tag1>", "The", "Company", "believes", "that", "a", "discussion", "of", "gross", "margin", ",", "representing", "operating", "revenue", "less", "cost", "of", "fuel", ",", "energy", "and", "capacity", "and", "natural", "gas", "purchased", "for", "resale", ",",...
[ "The", "Company", "believes", "that", "a", "discussion", "of", "gross", "margin", ",", "representing", "operating", "revenue", "less", "cost", "of", "fuel", ",", "energy", "and", "capacity", "and", "natural", "gas", "purchased", "for", "resale", ",", "is", "...
[ "Sierra", "Pacific", "believes", "that", "a", "discussion", "of", "gross", "margin", ",", "representing", "operating", "revenue", "less", "cost", "of", "fuel", ",", "energy", "and", "capacity", "and", "natural", "gas", "purchased", "for", "resale", ",", "is", ...
[]
[ "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 1, 1, -100, 0, -100, -100, -100, -...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
90144_16_item7_p46_s0
90144_15_item7_p51_s0
The Company is subject to federal, state and local laws and regulations regarding air and water quality, RPS , emissions performance standards, climate change, coal combustion byproduct disposal, hazardous and solid waste disposal, protected species and other environmental matters that have the potential to impact the ...
Sierra Pacific is subject to federal, state and local laws and regulations regarding air and water quality, RPS, emissions performance standards, climate change, coal combustion byproduct disposal, hazardous and solid waste disposal, protected species and other environmental matters that have the potential to impact Si...
2
[ "<tag1>", "The", "Company", "is", "subject", "to", "federal", ",", "state", "and", "local", "laws", "and", "regulations", "regarding", "air", "and", "water", "quality", ",", "RPS", ",", "emissions", "performance", "standards", ",", "climate", "change", ",", ...
[ "The", "Company", "is", "subject", "to", "federal", ",", "state", "and", "local", "laws", "and", "regulations", "regarding", "air", "and", "water", "quality", ",", "RPS", ",", "emissions", "performance", "standards", ",", "climate", "change", ",", "coal", "c...
[ "Sierra", "Pacific", "is", "subject", "to", "federal", ",", "state", "and", "local", "laws", "and", "regulations", "regarding", "air", "and", "water", "quality", ",", "RPS", ",", "emissions", "performance", "standards", ",", "climate", "change", ",", "coal", ...
[]
[ "Sierra", "Pacific", "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, ...
90144_16_item7_p46_s3
90144_15_item7_p51_s3
The Company believes it is in material compliance with all applicable laws and regulations, although many are subject to interpretation that may ultimately be resolved by the courts.
Sierra Pacific believes it is in material compliance with all applicable laws and regulations, although many are subject to interpretation that may ultimately be resolved by the courts.
2
[ "<tag1>", "The", "Company", "believes", "it", "is", "in", "material", "compliance", "with", "all", "applicable", "laws", "and", "regulations", ",", "although", "many", "are", "subject", "to", "interpretation", "that", "may", "ultimately", "be", "resolved", "by",...
[ "The", "Company", "believes", "it", "is", "in", "material", "compliance", "with", "all", "applicable", "laws", "and", "regulations", ",", "although", "many", "are", "subject", "to", "interpretation", "that", "may", "ultimately", "be", "resolved", "by", "the", ...
[ "Sierra", "Pacific", "believes", "it", "is", "in", "material", "compliance", "with", "all", "applicable", "laws", "and", "regulations", ",", "although", "many", "are", "subject", "to", "interpretation", "that", "may", "ultimately", "be", "resolved", "by", "the",...
[]
[ "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 1, 1, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_16_item7_p46_s5
90144_15_item7_p51_s4
Refer to "Liquidity and Capital Resources" for discussion of the Company's forecasted environmental-related capital expenditures.
Refer to "Liquidity and Capital Resources" for discussion of Sierra Pacific 's forecasted environmental-related capital expenditures.
2
[ "<tag1>", "Refer", "to", "\"", "Liquidity", "and", "Capital", "Resources", "\"", "for", "discussion", "of", "the", "Company", "'s", "forecasted", "environmental", "-", "related", "capital", "expenditures", ".", "<tag2>", "Refer", "to", "\"", "Liquidity", "and", ...
[ "Refer", "to", "\"", "Liquidity", "and", "Capital", "Resources", "\"", "for", "discussion", "of", "the", "Company", "'s", "forecasted", "environmental", "-", "related", "capital", "expenditures", "." ]
[ "Refer", "to", "\"", "Liquidity", "and", "Capital", "Resources", "\"", "for", "discussion", "of", "Sierra", "Pacific", "'s", "forecasted", "environmental", "-", "related", "capital", "expenditures", "." ]
[]
[ "Sierra", "Pacific" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, 0, -100, -100, -100, 0, -100, -100, 1, 1, -100, -100, 0, -100, 0, 0, -100,...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_16_item7_p5_s0
90144_15_item7_p5_s0
A comparison of key results related to regulated electric gross margin for the years ended December 31 is as follows:
A comparison of Sierra Pacific 's key operating results related to regulated electric gross margin for the years ended December 31 is as follows:
2
[ "<tag1>", "A", "comparison", "of", "key", "results", "related", "to", "regulated", "electric", "gross", "margin", "for", "the", "years", "ended", "December", "31", "is", "as", "follows", ":", "<tag2>", "A", "comparison", "of", "Sierra", "Pacific", "'s", "key...
[ "A", "comparison", "of", "key", "results", "related", "to", "regulated", "electric", "gross", "margin", "for", "the", "years", "ended", "December", "31", "is", "as", "follows", ":" ]
[ "A", "comparison", "of", "Sierra", "Pacific", "'s", "key", "operating", "results", "related", "to", "regulated", "electric", "gross", "margin", "for", "the", "years", "ended", "December", "31", "is", "as", "follows", ":" ]
[]
[ "Sierra", "Pacific", "'s", "operating" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, 0, 0, 1, 1, 1, -100, 1, -100, -100, 0, -100, 0, -100, -100, 0, 0, 0, 0, 0, 0, -100, -100,...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_16_item7_p7_s0
90144_15_item7_p5_s0
A comparison of key results related to regulated electric gross margin for the years ended December 31 is as follows:
A comparison of key results related to regulated natural gas gross margin for the years ended December 31 is as follows:
2
[ "<tag1>", "A", "comparison", "of", "key", "results", "related", "to", "regulated", "electric", "gross", "margin", "for", "the", "years", "ended", "December", "31", "is", "as", "follows", ":", "<tag2>", "A", "comparison", "of", "key", "results", "related", "t...
[ "A", "comparison", "of", "key", "results", "related", "to", "regulated", "electric", "gross", "margin", "for", "the", "years", "ended", "December", "31", "is", "as", "follows", ":" ]
[ "A", "comparison", "of", "key", "results", "related", "to", "regulated", "natural", "gas", "gross", "margin", "for", "the", "years", "ended", "December", "31", "is", "as", "follows", ":" ]
[]
[ "natural", "gas" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, -100, -100, -100, 0, 1, 1, -100, -100, -100, -100, -100, 0, 0, 0, 0, -100,...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_16_item7_p5_s0
90144_15_item7_p7_s0
A comparison of key results related to regulated natural gas gross margin for the years ended December 31 is as follows:
A comparison of Sierra Pacific 's key operating results related to regulated electric gross margin for the years ended December 31 is as follows:
2
[ "<tag1>", "A", "comparison", "of", "key", "results", "related", "to", "regulated", "natural", "gas", "gross", "margin", "for", "the", "years", "ended", "December", "31", "is", "as", "follows", ":", "<tag2>", "A", "comparison", "of", "Sierra", "Pacific", "'s"...
[ "A", "comparison", "of", "key", "results", "related", "to", "regulated", "natural", "gas", "gross", "margin", "for", "the", "years", "ended", "December", "31", "is", "as", "follows", ":" ]
[ "A", "comparison", "of", "Sierra", "Pacific", "'s", "key", "operating", "results", "related", "to", "regulated", "electric", "gross", "margin", "for", "the", "years", "ended", "December", "31", "is", "as", "follows", ":" ]
[]
[ "Sierra", "Pacific", "'s", "operating", "electric" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, 0, 0, 1, 1, 1, 0, 1, 0, -100, 0, -100, 1, 0, -100, 0, 0, 0, -100, 0, 0, 0, 0, -...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_17_item7_p32_s0
90144_16_item7_p26_s0
Net cash flows from operating activities for the years ended December 31 , 2015 and 2014 were $342 million and $246 million , respectively.
Net cash flows from investing activities for the years ended December 31 , 2015 and 2014 were $(250) million and $(186) million , respectively.
2
[ "<tag1>", "Net", "cash", "flows", "from", "operating", "activities", "for", "the", "years", "ended", "December", "31", ",", "2015", "and", "2014", "were", "$", "342", "million", "and", "$", "246", "million", ",", "respectively", ".", "<tag2>", "Net", "cash...
[ "Net", "cash", "flows", "from", "operating", "activities", "for", "the", "years", "ended", "December", "31", ",", "2015", "and", "2014", "were", "$", "342", "million", "and", "$", "246", "million", ",", "respectively", "." ]
[ "Net", "cash", "flows", "from", "investing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2015", "and", "2014", "were", "$", "(", "250", ")", "million", "and", "$", "(", "186", ")", "million", ",", "respectively", "." ]
[]
[ "investing", "250", "186" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, 0, -100, 1, -100, 0, -100, -100, 0, -100, 0, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_17_item7_p34_s0
90144_16_item7_p26_s0
Net cash flows from operating activities for the years ended December 31 , 2015 and 2014 were $342 million and $246 million , respectively.
Net cash flows from financing activities for the years ended December 31 , 2015 and 2014 were $(8) million and $(105) million , respectively.
2
[ "<tag1>", "Net", "cash", "flows", "from", "operating", "activities", "for", "the", "years", "ended", "December", "31", ",", "2015", "and", "2014", "were", "$", "342", "million", "and", "$", "246", "million", ",", "respectively", ".", "<tag2>", "Net", "cash...
[ "Net", "cash", "flows", "from", "operating", "activities", "for", "the", "years", "ended", "December", "31", ",", "2015", "and", "2014", "were", "$", "342", "million", "and", "$", "246", "million", ",", "respectively", "." ]
[ "Net", "cash", "flows", "from", "financing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2015", "and", "2014", "were", "$", "(", "8)", "million", "and", "$", "(", "105", ")", "million", ",", "respectively", "." ]
[]
[ "financing", "8)", "105" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, 0, -100, -100, 1, -100, 0, -100, -100, 0, -100, -100, 0, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_17_item7_p27_s0
90144_16_item7_p31_s0
Net cash flows from investing activities for the years ended December 31 , 2015 and 2014 were $(250) million and $(186) million , respectively.
Net cash flows from operating activities for the years ended December 31 , 2015 and 2014 were $342 million and $246 million , respectively.
2
[ "<tag1>", "Net", "cash", "flows", "from", "investing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2015", "and", "2014", "were", "$", "(", "250", ")", "million", "and", "$", "(", "186", ")", "million", ",", "respectively", ".", ...
[ "Net", "cash", "flows", "from", "investing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2015", "and", "2014", "were", "$", "(", "250", ")", "million", "and", "$", "(", "186", ")", "million", ",", "respectively", "." ]
[ "Net", "cash", "flows", "from", "operating", "activities", "for", "the", "years", "ended", "December", "31", ",", "2015", "and", "2014", "were", "$", "342", "million", "and", "$", "246", "million", ",", "respectively", "." ]
[]
[ "operating" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, 1, -100, -100, -10...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_17_item7_p34_s0
90144_16_item7_p31_s0
Net cash flows from investing activities for the years ended December 31 , 2015 and 2014 were $(250) million and $(186) million , respectively.
Net cash flows from financing activities for the years ended December 31 , 2015 and 2014 were $(8) million and $(105) million , respectively.
2
[ "<tag1>", "Net", "cash", "flows", "from", "investing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2015", "and", "2014", "were", "$", "(", "250", ")", "million", "and", "$", "(", "186", ")", "million", ",", "respectively", ".", ...
[ "Net", "cash", "flows", "from", "investing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2015", "and", "2014", "were", "$", "(", "250", ")", "million", "and", "$", "(", "186", ")", "million", ",", "respectively", "." ]
[ "Net", "cash", "flows", "from", "financing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2015", "and", "2014", "were", "$", "(", "8)", "million", "and", "$", "(", "105", ")", "million", ",", "respectively", "." ]
[]
[ "financing", "8)" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, 0, -100, 1, 0, -100, -100, -...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
90144_17_item7_p27_s0
90144_16_item7_p33_s0
Net cash flows from financing activities for the years ended December 31 , 2015 and 2014 were $(8) million and $(105) million , respectively.
Net cash flows from operating activities for the years ended December 31 , 2015 and 2014 were $342 million and $246 million , respectively.
2
[ "<tag1>", "Net", "cash", "flows", "from", "financing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2015", "and", "2014", "were", "$", "(", "8)", "million", "and", "$", "(", "105", ")", "million", ",", "respectively", ".", "<tag2...
[ "Net", "cash", "flows", "from", "financing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2015", "and", "2014", "were", "$", "(", "8)", "million", "and", "$", "(", "105", ")", "million", ",", "respectively", "." ]
[ "Net", "cash", "flows", "from", "operating", "activities", "for", "the", "years", "ended", "December", "31", ",", "2015", "and", "2014", "were", "$", "342", "million", "and", "$", "246", "million", ",", "respectively", "." ]
[]
[ "operating" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, 1, 0, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_17_item7_p32_s0
90144_16_item7_p33_s0
Net cash flows from financing activities for the years ended December 31 , 2015 and 2014 were $(8) million and $(105) million , respectively.
Net cash flows from investing activities for the years ended December 31 , 2015 and 2014 were $(250) million and $(186) million , respectively.
2
[ "<tag1>", "Net", "cash", "flows", "from", "financing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2015", "and", "2014", "were", "$", "(", "8)", "million", "and", "$", "(", "105", ")", "million", ",", "respectively", ".", "<tag2...
[ "Net", "cash", "flows", "from", "financing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2015", "and", "2014", "were", "$", "(", "8)", "million", "and", "$", "(", "105", ")", "million", ",", "respectively", "." ]
[ "Net", "cash", "flows", "from", "investing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2015", "and", "2014", "were", "$", "(", "250", ")", "million", "and", "$", "(", "186", ")", "million", ",", "respectively", "." ]
[]
[ "investing" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, 1, -100, -100, 0, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
90144_17_item7_p43_s1
90144_16_item7_p43_s0
(1) Not reflected on the Consolidated Balance Sheets.
(2) Interest is not reflected on the Consolidated Balance Sheets.
2
[ "<tag1>", "(", "1", ")", "Not", "reflected", "on", "the", "Consolidated", "Balance", "Sheets", ".", "<tag2>", "(", "2", ")", "Interest", "is", "not", "reflected", "on", "the", "Consolidated", "Balance", "Sheets", ".", "<tag3>" ]
[ "(", "1", ")", "Not", "reflected", "on", "the", "Consolidated", "Balance", "Sheets", "." ]
[ "(", "2", ")", "Interest", "is", "not", "reflected", "on", "the", "Consolidated", "Balance", "Sheets", "." ]
[]
[ "Interest" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, 1, -100, 0, -100, -100, 0, -100, -100, -100, 0, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_17_item7_p43_s0
90144_16_item7_p43_s1
(2) Interest is not reflected on the Consolidated Balance Sheets.
(1) Not reflected on the Consolidated Balance Sheets.
2
[ "<tag1>", "(", "2", ")", "Interest", "is", "not", "reflected", "on", "the", "Consolidated", "Balance", "Sheets", ".", "<tag2>", "(", "1", ")", "Not", "reflected", "on", "the", "Consolidated", "Balance", "Sheets", ".", "<tag3>" ]
[ "(", "2", ")", "Interest", "is", "not", "reflected", "on", "the", "Consolidated", "Balance", "Sheets", "." ]
[ "(", "1", ")", "Not", "reflected", "on", "the", "Consolidated", "Balance", "Sheets", "." ]
[]
[]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_17_item7_p7_s0
90144_16_item7_p5_s0
A comparison of Sierra Pacific 's key operating results related to regulated electric gross margin for the years ended December 31 is as follows:
A comparison of key results related to regulated natural gas gross margin for the years ended December 31 is as follows:
2
[ "<tag1>", "A", "comparison", "of", "Sierra", "Pacific", "'s", "key", "operating", "results", "related", "to", "regulated", "electric", "gross", "margin", "for", "the", "years", "ended", "December", "31", "is", "as", "follows", ":", "<tag2>", "A", "comparison",...
[ "A", "comparison", "of", "Sierra", "Pacific", "'s", "key", "operating", "results", "related", "to", "regulated", "electric", "gross", "margin", "for", "the", "years", "ended", "December", "31", "is", "as", "follows", ":" ]
[ "A", "comparison", "of", "key", "results", "related", "to", "regulated", "natural", "gas", "gross", "margin", "for", "the", "years", "ended", "December", "31", "is", "as", "follows", ":" ]
[]
[ "natural", "gas" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, 0, 0, 0, -100, -100, -100, 0, 1, 1, 0, -100, -100, -100, 0, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_17_item7_p5_s0
90144_16_item7_p7_s0
A comparison of key results related to regulated natural gas gross margin for the years ended December 31 is as follows:
A comparison of Sierra Pacific 's key operating results related to regulated electric gross margin for the years ended December 31 is as follows:
2
[ "<tag1>", "A", "comparison", "of", "key", "results", "related", "to", "regulated", "natural", "gas", "gross", "margin", "for", "the", "years", "ended", "December", "31", "is", "as", "follows", ":", "<tag2>", "A", "comparison", "of", "Sierra", "Pacific", "'s"...
[ "A", "comparison", "of", "key", "results", "related", "to", "regulated", "natural", "gas", "gross", "margin", "for", "the", "years", "ended", "December", "31", "is", "as", "follows", ":" ]
[ "A", "comparison", "of", "Sierra", "Pacific", "'s", "key", "operating", "results", "related", "to", "regulated", "electric", "gross", "margin", "for", "the", "years", "ended", "December", "31", "is", "as", "follows", ":" ]
[]
[ "Sierra", "Pacific", "'s", "operating", "electric" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, 0, 0, 1, 1, 1, -100, 1, 0, 0, 0, 0, 1, 0, 0, -100, -100, -100, 0, 0, 0, 0, 0, -...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_18_item7_p15_s2
90144_17_item7_p23_s2
The increase in the effective tax rate is primarily due to the effects of ratemaking.
The decrease in the effective tax rate is primarily due to the effects of 2017 Tax Reform.
2
[ "<tag1>", "The", "increase", "in", "the", "effective", "tax", "rate", "is", "primarily", "due", "to", "the", "effects", "of", "ratemaking", ".", "<tag2>", "The", "decrease", "in", "the", "effective", "tax", "rate", "is", "primarily", "due", "to", "the", "e...
[ "The", "increase", "in", "the", "effective", "tax", "rate", "is", "primarily", "due", "to", "the", "effects", "of", "ratemaking", "." ]
[ "The", "decrease", "in", "the", "effective", "tax", "rate", "is", "primarily", "due", "to", "the", "effects", "of", "2017", "Tax", "Reform", "." ]
[]
[ "decrease", "2017", "Tax", "Reform" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, 1, 0, 0, 0, 0, 0, -100, 0, 0, 0, 0, 0, 0, 1, 1, 1, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_18_item7_p32_s0
90144_17_item7_p26_s0
Net cash flows from operating activities for the years ended December 31 , 2016 and 2015 were $243 million and $342 million , respectively.
Net cash flows from investing activities for the years ended December 31 , 2016 and 2015 were $(194) million and $(250) million , respectively.
2
[ "<tag1>", "Net", "cash", "flows", "from", "operating", "activities", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "were", "$", "243", "million", "and", "$", "342", "million", ",", "respectively", ".", "<tag2>", "Net", "cash...
[ "Net", "cash", "flows", "from", "operating", "activities", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "were", "$", "243", "million", "and", "$", "342", "million", ",", "respectively", "." ]
[ "Net", "cash", "flows", "from", "investing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "were", "$", "(", "194", ")", "million", "and", "$", "(", "250", ")", "million", ",", "respectively", "." ]
[]
[ "investing", "194", "250" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, 0, -100, 0, 1, -100, -100, -100, 0, -100, -100, 0, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_18_item7_p34_s0
90144_17_item7_p26_s0
Net cash flows from operating activities for the years ended December 31 , 2016 and 2015 were $243 million and $342 million , respectively.
Net cash flows from financing activities for the years ended December 31 , 2016 and 2015 were $(100) million and $(8) million , respectively.
2
[ "<tag1>", "Net", "cash", "flows", "from", "operating", "activities", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "were", "$", "243", "million", "and", "$", "342", "million", ",", "respectively", ".", "<tag2>", "Net", "cash...
[ "Net", "cash", "flows", "from", "operating", "activities", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "were", "$", "243", "million", "and", "$", "342", "million", ",", "respectively", "." ]
[ "Net", "cash", "flows", "from", "financing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "were", "$", "(", "100", ")", "million", "and", "$", "(", "8)", "million", ",", "respectively", "." ]
[]
[ "financing", "100", "8)" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, 0, -100, 1, 0, -100, -100, -100, 0, -100, 0, 0, -1...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_18_item7_p27_s0
90144_17_item7_p31_s0
Net cash flows from investing activities for the years ended December 31 , 2016 and 2015 were $(194) million and $(250) million , respectively.
Net cash flows from operating activities for the years ended December 31 , 2016 and 2015 were $243 million and $342 million , respectively.
2
[ "<tag1>", "Net", "cash", "flows", "from", "investing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "were", "$", "(", "194", ")", "million", "and", "$", "(", "250", ")", "million", ",", "respectively", ".", ...
[ "Net", "cash", "flows", "from", "investing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "were", "$", "(", "194", ")", "million", "and", "$", "(", "250", ")", "million", ",", "respectively", "." ]
[ "Net", "cash", "flows", "from", "operating", "activities", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "were", "$", "243", "million", "and", "$", "342", "million", ",", "respectively", "." ]
[]
[ "operating" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, 0, 0, 1, -100, -100, -100, -...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_18_item7_p34_s0
90144_17_item7_p31_s0
Net cash flows from investing activities for the years ended December 31 , 2016 and 2015 were $(194) million and $(250) million , respectively.
Net cash flows from financing activities for the years ended December 31 , 2016 and 2015 were $(100) million and $(8) million , respectively.
2
[ "<tag1>", "Net", "cash", "flows", "from", "investing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "were", "$", "(", "194", ")", "million", "and", "$", "(", "250", ")", "million", ",", "respectively", ".", ...
[ "Net", "cash", "flows", "from", "investing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "were", "$", "(", "194", ")", "million", "and", "$", "(", "250", ")", "million", ",", "respectively", "." ]
[ "Net", "cash", "flows", "from", "financing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "were", "$", "(", "100", ")", "million", "and", "$", "(", "8)", "million", ",", "respectively", "." ]
[]
[ "financing", "8)" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, 0, 1, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
90144_18_item7_p27_s0
90144_17_item7_p33_s0
Net cash flows from financing activities for the years ended December 31 , 2016 and 2015 were $(100) million and $(8) million , respectively.
Net cash flows from operating activities for the years ended December 31 , 2016 and 2015 were $243 million and $342 million , respectively.
2
[ "<tag1>", "Net", "cash", "flows", "from", "financing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "were", "$", "(", "100", ")", "million", "and", "$", "(", "8)", "million", ",", "respectively", ".", "<tag2...
[ "Net", "cash", "flows", "from", "financing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "were", "$", "(", "100", ")", "million", "and", "$", "(", "8)", "million", ",", "respectively", "." ]
[ "Net", "cash", "flows", "from", "operating", "activities", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "were", "$", "243", "million", "and", "$", "342", "million", ",", "respectively", "." ]
[]
[ "operating" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, 0, -100, 1, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_18_item7_p32_s0
90144_17_item7_p33_s0
Net cash flows from financing activities for the years ended December 31 , 2016 and 2015 were $(100) million and $(8) million , respectively.
Net cash flows from investing activities for the years ended December 31 , 2016 and 2015 were $(194) million and $(250) million , respectively.
2
[ "<tag1>", "Net", "cash", "flows", "from", "financing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "were", "$", "(", "100", ")", "million", "and", "$", "(", "8)", "million", ",", "respectively", ".", "<tag2...
[ "Net", "cash", "flows", "from", "financing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "were", "$", "(", "100", ")", "million", "and", "$", "(", "8)", "million", ",", "respectively", "." ]
[ "Net", "cash", "flows", "from", "investing", "activities", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "were", "$", "(", "194", ")", "million", "and", "$", "(", "250", ")", "million", ",", "respectively", "." ]
[]
[ "investing" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, 1, -100, -100, -100, -10...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
90144_18_item7_p43_s1
90144_17_item7_p43_s0
(1) Not reflected on the Consolidated Balance Sheets.
(2) Interest is not reflected on the Consolidated Balance Sheets.
2
[ "<tag1>", "(", "1", ")", "Not", "reflected", "on", "the", "Consolidated", "Balance", "Sheets", ".", "<tag2>", "(", "2", ")", "Interest", "is", "not", "reflected", "on", "the", "Consolidated", "Balance", "Sheets", ".", "<tag3>" ]
[ "(", "1", ")", "Not", "reflected", "on", "the", "Consolidated", "Balance", "Sheets", "." ]
[ "(", "2", ")", "Interest", "is", "not", "reflected", "on", "the", "Consolidated", "Balance", "Sheets", "." ]
[]
[ "Interest" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, -100, -100, 1, -100, 0, 0, -100, -100, -100, -100, -100, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_18_item7_p43_s0
90144_17_item7_p43_s1
(2) Interest is not reflected on the Consolidated Balance Sheets.
(1) Not reflected on the Consolidated Balance Sheets.
2
[ "<tag1>", "(", "2", ")", "Interest", "is", "not", "reflected", "on", "the", "Consolidated", "Balance", "Sheets", ".", "<tag2>", "(", "1", ")", "Not", "reflected", "on", "the", "Consolidated", "Balance", "Sheets", ".", "<tag3>" ]
[ "(", "2", ")", "Interest", "is", "not", "reflected", "on", "the", "Consolidated", "Balance", "Sheets", "." ]
[ "(", "1", ")", "Not", "reflected", "on", "the", "Consolidated", "Balance", "Sheets", "." ]
[]
[]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_18_item7_p46_s2
90144_17_item7_p46_s2
These laws and regulations are administered by the EPA and various state and local agencies.
These laws and regulations are administered by various federal, state and local agencies.
2
[ "<tag1>", "These", "laws", "and", "regulations", "are", "administered", "by", "the", "EPA", "and", "various", "state", "and", "local", "agencies", ".", "<tag2>", "These", "laws", "and", "regulations", "are", "administered", "by", "various", "federal", ",", "st...
[ "These", "laws", "and", "regulations", "are", "administered", "by", "the", "EPA", "and", "various", "state", "and", "local", "agencies", "." ]
[ "These", "laws", "and", "regulations", "are", "administered", "by", "various", "federal", ",", "state", "and", "local", "agencies", "." ]
[]
[ "federal" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, 0, -100, -100, -100, -100, -100, 0, 1, -100, 0, -100, -100, -100, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_18_item7_p7_s0
90144_17_item7_p5_s0
A comparison of Sierra Pacific 's key operating results related to regulated electric gross margin for the years ended December 31 is as follows:
A comparison of key results related to regulated natural gas gross margin for the years ended December 31 is as follows:
2
[ "<tag1>", "A", "comparison", "of", "Sierra", "Pacific", "'s", "key", "operating", "results", "related", "to", "regulated", "electric", "gross", "margin", "for", "the", "years", "ended", "December", "31", "is", "as", "follows", ":", "<tag2>", "A", "comparison",...
[ "A", "comparison", "of", "Sierra", "Pacific", "'s", "key", "operating", "results", "related", "to", "regulated", "electric", "gross", "margin", "for", "the", "years", "ended", "December", "31", "is", "as", "follows", ":" ]
[ "A", "comparison", "of", "key", "results", "related", "to", "regulated", "natural", "gas", "gross", "margin", "for", "the", "years", "ended", "December", "31", "is", "as", "follows", ":" ]
[]
[ "natural", "gas" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, 0, 0, -100, -100, -100, 0, -100, 1, 1, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
90144_18_item7_p64_s1
90144_17_item7_p64_s1
As of December 31 , 2016 , these amounts were recognized as regulatory assets of $85 million and regulatory liabilities of $6 million , and will be included in regulated rates when the temporary differences reverse.
As of December 31 , 2017 , these amounts were recognized as a net regulatory liability of $264 million and will be included in regulated rates when the temporary differences reverse.
2
[ "<tag1>", "As", "of", "December", "31", ",", "2016", ",", "these", "amounts", "were", "recognized", "as", "regulatory", "assets", "of", "$", "85", "million", "and", "regulatory", "liabilities", "of", "$", "6", "million", ",", "and", "will", "be", "included...
[ "As", "of", "December", "31", ",", "2016", ",", "these", "amounts", "were", "recognized", "as", "regulatory", "assets", "of", "$", "85", "million", "and", "regulatory", "liabilities", "of", "$", "6", "million", ",", "and", "will", "be", "included", "in", ...
[ "As", "of", "December", "31", ",", "2017", ",", "these", "amounts", "were", "recognized", "as", "a", "net", "regulatory", "liability", "of", "$", "264", "million", "and", "will", "be", "included", "in", "regulated", "rates", "when", "the", "temporary", "di...
[]
[ "net", "liability" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
90144_18_item7_p5_s0
90144_17_item7_p7_s0
A comparison of key results related to regulated natural gas gross margin for the years ended December 31 is as follows:
A comparison of Sierra Pacific 's key operating results related to regulated electric gross margin for the years ended December 31 is as follows:
2
[ "<tag1>", "A", "comparison", "of", "key", "results", "related", "to", "regulated", "natural", "gas", "gross", "margin", "for", "the", "years", "ended", "December", "31", "is", "as", "follows", ":", "<tag2>", "A", "comparison", "of", "Sierra", "Pacific", "'s"...
[ "A", "comparison", "of", "key", "results", "related", "to", "regulated", "natural", "gas", "gross", "margin", "for", "the", "years", "ended", "December", "31", "is", "as", "follows", ":" ]
[ "A", "comparison", "of", "Sierra", "Pacific", "'s", "key", "operating", "results", "related", "to", "regulated", "electric", "gross", "margin", "for", "the", "years", "ended", "December", "31", "is", "as", "follows", ":" ]
[]
[ "Sierra", "Pacific", "'s", "operating", "electric" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, -100, -100, 1, 1, 1, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, -100, 0, 0, 0, 0, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
906709_12_item7_p6_s0
906709_11_item7_p7_s0
drug research and development is an inherently uncertain process and there is a high risk of failure at every stage prior to approval and the timing and outcome of clinical trial results is extremely difficult to predict.
While we believe that our substantial investment in research and development has the potential to create significant value if one or more of our drug candidates demonstrates positive clinical results and/or receives regulatory approval in one or more major markets, drug research and development is an inherently uncerta...
2
[ "<tag1>", "drug", "research", "and", "development", "is", "an", "inherently", "uncertain", "process", "and", "there", "is", "a", "high", "risk", "of", "failure", "at", "every", "stage", "prior", "to", "approval", "and", "the", "timing", "and", "outcome", "of...
[ "drug", "research", "and", "development", "is", "an", "inherently", "uncertain", "process", "and", "there", "is", "a", "high", "risk", "of", "failure", "at", "every", "stage", "prior", "to", "approval", "and", "the", "timing", "and", "outcome", "of", "clinic...
[ "While", "we", "believe", "that", "our", "substantial", "investment", "in", "research", "and", "development", "has", "the", "potential", "to", "create", "significant", "value", "if", "one", "or", "more", "of", "our", "drug", "candidates", "demonstrates", "positi...
[]
[ "believe", "substantial", "investment", "potential", "create", "significant", "value", "one", "candidates", "demonstrates", "positive", "and/or", "receives", "regulatory", "one", "major", "markets" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
906709_13_item7_p47_s4
906709_12_item7_p10_s1
On February 29, 2012, we sold all of our rights to receive future royalty payments on CIMZIA and MIRCERA in exchange for $124.0 million.
Cash flows used in financing activities On February 24, 2012, we sold all of our rights to receive future royalty payments on CIMZIA and MIRCERA in exchange for $124.0 million.
2
[ "<tag1>", "On", "February", "29", ",", "2012", ",", "we", "sold", "all", "of", "our", "rights", "to", "receive", "future", "royalty", "payments", "on", "CIMZIA", "and", "MIRCERA", "in", "exchange", "for", "$", "124.0", "million", ".", "<tag2>", "Cash", "...
[ "On", "February", "29", ",", "2012", ",", "we", "sold", "all", "of", "our", "rights", "to", "receive", "future", "royalty", "payments", "on", "CIMZIA", "and", "MIRCERA", "in", "exchange", "for", "$", "124.0", "million", "." ]
[ "Cash", "flows", "used", "in", "financing", "activities", "On", "February", "24", ",", "2012", ",", "we", "sold", "all", "of", "our", "rights", "to", "receive", "future", "royalty", "payments", "on", "CIMZIA", "and", "MIRCERA", "in", "exchange", "for", "$"...
[]
[ "Cash", "flows", "used", "financing", "activities" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 1, 1, 1, -100, 1, 1, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
906709_13_item7_p19_s4
906709_12_item7_p12_s0
Management makes its best estimate of the period over which we expect to fulfill our performance obligations.
We make our best estimate of the period over which we expect to fulfill our performance obligations.
2
[ "<tag1>", "Management", "makes", "its", "best", "estimate", "of", "the", "period", "over", "which", "we", "expect", "to", "fulfill", "our", "performance", "obligations", ".", "<tag2>", "We", "make", "our", "best", "estimate", "of", "the", "period", "over", "...
[ "Management", "makes", "its", "best", "estimate", "of", "the", "period", "over", "which", "we", "expect", "to", "fulfill", "our", "performance", "obligations", "." ]
[ "We", "make", "our", "best", "estimate", "of", "the", "period", "over", "which", "we", "expect", "to", "fulfill", "our", "performance", "obligations", "." ]
[]
[ "make" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, 1, 0, -100, -100, -100, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, 0, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
906709_13_item7_p3_s1
906709_12_item7_p1_s5
We are a party to an exclusive worldwide license agreement with AstraZeneca for the global development and commercialization of NKTR-118 and NKTR-119.
We are a party to an exclusive worldwide license agreement with AstraZeneca for the global development and commercialization of naloxegol and naloxegol fixed-dose combination products (formerly known as NKTR-119).
2
[ "<tag1>", "We", "are", "a", "party", "to", "an", "exclusive", "worldwide", "license", "agreement", "with", "AstraZeneca", "for", "the", "global", "development", "and", "commercialization", "of", "NKTR-118", "and", "NKTR-119", ".", "<tag2>", "We", "are", "a", "...
[ "We", "are", "a", "party", "to", "an", "exclusive", "worldwide", "license", "agreement", "with", "AstraZeneca", "for", "the", "global", "development", "and", "commercialization", "of", "NKTR-118", "and", "NKTR-119", "." ]
[ "We", "are", "a", "party", "to", "an", "exclusive", "worldwide", "license", "agreement", "with", "AstraZeneca", "for", "the", "global", "development", "and", "commercialization", "of", "naloxegol", "and", "naloxegol", "fixed", "-", "dose", "combination", "products...
[]
[ "naloxegol", "naloxegol", "fixed", "dose", "combination", "products", "formerly", "known" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, 0, -100, 0, 0, 0, -100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 1, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
906709_13_item7_p32_s3
906709_12_item7_p24_s6
At the same time, we continue to advance the Phase 2 clinical study for NKTR-102 in colorectal cancer patients.
At the same time, we continue to advance the Phase 2 clinical study for etirinotecan pegol in colorectal cancer patients.
2
[ "<tag1>", "At", "the", "same", "time", ",", "we", "continue", "to", "advance", "the", "Phase", "2", "clinical", "study", "for", "NKTR-102", "in", "colorectal", "cancer", "patients", ".", "<tag2>", "At", "the", "same", "time", ",", "we", "continue", "to", ...
[ "At", "the", "same", "time", ",", "we", "continue", "to", "advance", "the", "Phase", "2", "clinical", "study", "for", "NKTR-102", "in", "colorectal", "cancer", "patients", "." ]
[ "At", "the", "same", "time", ",", "we", "continue", "to", "advance", "the", "Phase", "2", "clinical", "study", "for", "etirinotecan", "pegol", "in", "colorectal", "cancer", "patients", "." ]
[]
[ "etirinotecan", "pegol" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, 1, 1, 0, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
906709_13_item7_p32_s13
906709_12_item7_p25_s3
Under our collaboration agreement with Bayer, we are responsible for all clinical and commercial supply of the nebulizer devices for Amikacin Inhale.
Under our collaboration agreement with Bayer, we are responsible for all clinical and commercial supply of the nebulizer devices for this drug candidate.
2
[ "<tag1>", "Under", "our", "collaboration", "agreement", "with", "Bayer", ",", "we", "are", "responsible", "for", "all", "clinical", "and", "commercial", "supply", "of", "the", "nebulizer", "devices", "for", "Amikacin", "Inhale", ".", "<tag2>", "Under", "our", ...
[ "Under", "our", "collaboration", "agreement", "with", "Bayer", ",", "we", "are", "responsible", "for", "all", "clinical", "and", "commercial", "supply", "of", "the", "nebulizer", "devices", "for", "Amikacin", "Inhale", "." ]
[ "Under", "our", "collaboration", "agreement", "with", "Bayer", ",", "we", "are", "responsible", "for", "all", "clinical", "and", "commercial", "supply", "of", "the", "nebulizer", "devices", "for", "this", "drug", "candidate", "." ]
[]
[ "drug", "candidate" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, 0, -100, 0, -100, -100, -100, -100, -100, -100, -100, 0, -100, -100, 0...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
906709_13_item7_p32_s14
906709_12_item7_p25_s4
We do not expect to have any significant future research and development costs associated with NKTR-118 and NKTR-119 as AstraZeneca is responsible for all further development and commercialization costs for these drug candidates.
We do not expect to have any significant future research and development costs associated with naloxegol or the naloxegol fixed-dose combination products as AstraZeneca is responsible for all further development and commercialization costs for these drug candidates.
2
[ "<tag1>", "We", "do", "not", "expect", "to", "have", "any", "significant", "future", "research", "and", "development", "costs", "associated", "with", "NKTR-118", "and", "NKTR-119", "as", "AstraZeneca", "is", "responsible", "for", "all", "further", "development", ...
[ "We", "do", "not", "expect", "to", "have", "any", "significant", "future", "research", "and", "development", "costs", "associated", "with", "NKTR-118", "and", "NKTR-119", "as", "AstraZeneca", "is", "responsible", "for", "all", "further", "development", "and", "c...
[ "We", "do", "not", "expect", "to", "have", "any", "significant", "future", "research", "and", "development", "costs", "associated", "with", "naloxegol", "or", "the", "naloxegol", "fixed", "-", "dose", "combination", "products", "as", "AstraZeneca", "is", "respon...
[]
[ "naloxegol", "naloxegol", "fixed", "dose", "combination", "products" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, 0, -10...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
906709_13_item7_p32_s16
906709_12_item7_p25_s6
Our discovery research organization is identifying new drug candidates by applying our technology platform to a wide range of molecule classes, including small molecules and large proteins, peptides and antibodies, across multiple therapeutic areas.
Our discovery research organization is identifying new drug candidates by applying our pegylation technology platform to a wide range of molecule classes, including small molecules and large proteins, peptides and antibodies, across multiple therapeutic areas.
2
[ "<tag1>", "Our", "discovery", "research", "organization", "is", "identifying", "new", "drug", "candidates", "by", "applying", "our", "technology", "platform", "to", "a", "wide", "range", "of", "molecule", "classes", ",", "including", "small", "molecules", "and", ...
[ "Our", "discovery", "research", "organization", "is", "identifying", "new", "drug", "candidates", "by", "applying", "our", "technology", "platform", "to", "a", "wide", "range", "of", "molecule", "classes", ",", "including", "small", "molecules", "and", "large", ...
[ "Our", "discovery", "research", "organization", "is", "identifying", "new", "drug", "candidates", "by", "applying", "our", "pegylation", "technology", "platform", "to", "a", "wide", "range", "of", "molecule", "classes", ",", "including", "small", "molecules", "and...
[]
[ "pegylation" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
906709_13_item7_p34_s1
906709_12_item7_p27_s1
Furthermore, our strategy includes entering into collaborations with third parties to participate in the development and commercialization of some of our drug candidates such as those collaborations that we have already completed for NKTR-118, NKTR-119 and Amikacin Inhale.
Furthermore, our strategy includes the potential of entering into collaborations with third parties to participate in the development and commercialization of some of our drug candidates such as those collaborations that we have already completed for naloxegol and Amikacin Inhale.
2
[ "<tag1>", "Furthermore", ",", "our", "strategy", "includes", "entering", "into", "collaborations", "with", "third", "parties", "to", "participate", "in", "the", "development", "and", "commercialization", "of", "some", "of", "our", "drug", "candidates", "such", "as...
[ "Furthermore", ",", "our", "strategy", "includes", "entering", "into", "collaborations", "with", "third", "parties", "to", "participate", "in", "the", "development", "and", "commercialization", "of", "some", "of", "our", "drug", "candidates", "such", "as", "those"...
[ "Furthermore", ",", "our", "strategy", "includes", "the", "potential", "of", "entering", "into", "collaborations", "with", "third", "parties", "to", "participate", "in", "the", "development", "and", "commercialization", "of", "some", "of", "our", "drug", "candidat...
[]
[ "potential", "naloxegol" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
906709_13_item7_p47_s4
906709_12_item7_p34_s0
On February 29, 2012, we sold all of our rights to receive future royalty payments on CIMZIA and MIRCERA in exchange for $124.0 million.
Cash flows used in financing activities On February 24, 2012, we sold all of our rights to receive future royalty payments on CIMZIA and MIRCERA in exchange for $124.0 million.
2
[ "<tag1>", "On", "February", "29", ",", "2012", ",", "we", "sold", "all", "of", "our", "rights", "to", "receive", "future", "royalty", "payments", "on", "CIMZIA", "and", "MIRCERA", "in", "exchange", "for", "$", "124.0", "million", ".", "<tag2>", "Cash", "...
[ "On", "February", "29", ",", "2012", ",", "we", "sold", "all", "of", "our", "rights", "to", "receive", "future", "royalty", "payments", "on", "CIMZIA", "and", "MIRCERA", "in", "exchange", "for", "$", "124.0", "million", "." ]
[ "Cash", "flows", "used", "in", "financing", "activities", "On", "February", "24", ",", "2012", ",", "we", "sold", "all", "of", "our", "rights", "to", "receive", "future", "royalty", "payments", "on", "CIMZIA", "and", "MIRCERA", "in", "exchange", "for", "$"...
[]
[ "Cash", "flows", "used", "financing", "activities" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 1, 1, 1, 0, 1, 1, -100, -100, 0, -100, 0, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
906709_13_item7_p47_s0
906709_12_item7_p35_s0
During the year ended December 31, 2010, net cash used in operating activities totaled $55.9 million, which primarily consisted of spending on operating costs and expenses and includes $7.0 million for interest payments on our convertible subordinated notes, and was partially offset by a $50.0 million upfront payment r...
on our convertible subordinated notes, and was partially offset by a $50.0 million upfront payment received from Amgen under the supply, dedicated suite and manufacturing guarantee agreement that we entered into with Amgen in October 2010.
2
[ "<tag1>", "During", "the", "year", "ended", "December", "31", ",", "2010", ",", "net", "cash", "used", "in", "operating", "activities", "totaled", "$", "55.9", "million", ",", "which", "primarily", "consisted", "of", "spending", "on", "operating", "costs", "...
[ "During", "the", "year", "ended", "December", "31", ",", "2010", ",", "net", "cash", "used", "in", "operating", "activities", "totaled", "$", "55.9", "million", ",", "which", "primarily", "consisted", "of", "spending", "on", "operating", "costs", "and", "exp...
[ "on", "our", "convertible", "subordinated", "notes", ",", "and", "was", "partially", "offset", "by", "a", "$", "50.0", "million", "upfront", "payment", "received", "from", "Amgen", "under", "the", "supply", ",", "dedicated", "suite", "and", "manufacturing", "g...
[]
[]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, ...
906709_13_item7_p51_s3
906709_12_item7_p39_s2
This is further discussed in Note 6 of Item 8.
The sublease is discussed in Note 6 of Item 8.
2
[ "<tag1>", "This", "is", "further", "discussed", "in", "Note", "6", "of", "Item", "8", ".", "<tag2>", "The", "sublease", "is", "discussed", "in", "Note", "6", "of", "Item", "8", ".", "<tag3>" ]
[ "This", "is", "further", "discussed", "in", "Note", "6", "of", "Item", "8", "." ]
[ "The", "sublease", "is", "discussed", "in", "Note", "6", "of", "Item", "8", "." ]
[]
[ "sublease" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, 1, 0, -100, -100, 0, 0, -100, -100, -100, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
906709_13_item7_p50_s0
906709_12_item7_p40_s0
(3) In November 2010, we moved into our Mission Bay Facility, which includes our corporate headquarters and an R D center.
In November 2010, we moved into our Mission Bay Facility, which includes our corporate headquarters and a research and development center.
2
[ "<tag1>", "(", "3", ")", "In", "November", "2010", ",", "we", "moved", "into", "our", "Mission", "Bay", "Facility", ",", "which", "includes", "our", "corporate", "headquarters", "and", "an", "R", "D", "center", ".", "<tag2>", "In", "November", "2010", ",...
[ "(", "3", ")", "In", "November", "2010", ",", "we", "moved", "into", "our", "Mission", "Bay", "Facility", ",", "which", "includes", "our", "corporate", "headquarters", "and", "an", "R", "D", "center", "." ]
[ "In", "November", "2010", ",", "we", "moved", "into", "our", "Mission", "Bay", "Facility", ",", "which", "includes", "our", "corporate", "headquarters", "and", "a", "research", "and", "development", "center", "." ]
[]
[ "research", "development" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, 0, -100, -100, -100, -100, 0, -100, -100, -100, -100, 0, -100, -...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
906709_13_item7_p51_s0
906709_12_item7_p40_s1
Under the terms of the sublease we entered into with Pfizer Inc. on September 30, 2009 for the Mission Bay Facility, we will begin making non-cancelable lease payments in 2014.
September 30, 2009 for the Mission Bay Facility, we will begin making non-cancelable lease payments in 2014.
2
[ "<tag1>", "Under", "the", "terms", "of", "the", "sublease", "we", "entered", "into", "with", "Pfizer", "Inc.", "on", "September", "30", ",", "2009", "for", "the", "Mission", "Bay", "Facility", ",", "we", "will", "begin", "making", "non", "-", "cancelable",...
[ "Under", "the", "terms", "of", "the", "sublease", "we", "entered", "into", "with", "Pfizer", "Inc.", "on", "September", "30", ",", "2009", "for", "the", "Mission", "Bay", "Facility", ",", "we", "will", "begin", "making", "non", "-", "cancelable", "lease", ...
[ "September", "30", ",", "2009", "for", "the", "Mission", "Bay", "Facility", ",", "we", "will", "begin", "making", "non", "-", "cancelable", "lease", "payments", "in", "2014", "." ]
[]
[]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
906709_13_item7_p7_s1
906709_12_item7_p4_s0
Our second most advanced drug candidate, NKTR-102, is a next-generation topoisomerase I inhibitor, currently being evaluated as a single-agent therapy in a Phase 3 open-label, randomized, multicenter clinical study in patients with metastatic breast cancer.
Etirinotecan pegol is currently being evaluated as a single-agent therapy in a Phase 3 open-label, randomized, multicenter clinical study in patients with metastatic breast cancer.
2
[ "<tag1>", "Our", "second", "most", "advanced", "drug", "candidate", ",", "NKTR-102", ",", "is", "a", "next", "-", "generation", "topoisomerase", "I", "inhibitor", ",", "currently", "being", "evaluated", "as", "a", "single", "-", "agent", "therapy", "in", "a"...
[ "Our", "second", "most", "advanced", "drug", "candidate", ",", "NKTR-102", ",", "is", "a", "next", "-", "generation", "topoisomerase", "I", "inhibitor", ",", "currently", "being", "evaluated", "as", "a", "single", "-", "agent", "therapy", "in", "a", "Phase",...
[ "Etirinotecan", "pegol", "is", "currently", "being", "evaluated", "as", "a", "single", "-", "agent", "therapy", "in", "a", "Phase", "3", "open", "-", "label", ",", "randomized", ",", "multicenter", "clinical", "study", "in", "patients", "with", "metastatic", ...
[]
[ "Etirinotecan", "pegol" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
906709_13_item7_p9_s0
906709_12_item7_p5_s5
We also have a significant collaboration with Bayer Healthcare LLC (Bayer) for Amikacin Inhale, an inhaled solution of amikacin, an aminoglycoside antibiotic, that has completed Phase 2 development.
We have a significant collaboration with Bayer Healthcare LLC (Bayer) to develop BAY41-6551 (Amikacin Inhale, formerly known as NKTR-061), which is an inhaled solution of amikacin, an aminoglycoside antibiotic, that has completed Phase 2 clinical development.
2
[ "<tag1>", "We", "also", "have", "a", "significant", "collaboration", "with", "Bayer", "Healthcare", "LLC", "(", "Bayer", ")", "for", "Amikacin", "Inhale", ",", "an", "inhaled", "solution", "of", "amikacin", ",", "an", "aminoglycoside", "antibiotic", ",", "that...
[ "We", "also", "have", "a", "significant", "collaboration", "with", "Bayer", "Healthcare", "LLC", "(", "Bayer", ")", "for", "Amikacin", "Inhale", ",", "an", "inhaled", "solution", "of", "amikacin", ",", "an", "aminoglycoside", "antibiotic", ",", "that", "has", ...
[ "We", "have", "a", "significant", "collaboration", "with", "Bayer", "Healthcare", "LLC", "(", "Bayer", ")", "to", "develop", "BAY41", "-", "6551", "(", "Amikacin", "Inhale", ",", "formerly", "known", "as", "NKTR-061", ")", ",", "which", "is", "an", "inhale...
[]
[ "develop", "BAY41", "6551", "formerly", "known", "NKTR-061", "clinical" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, 0, -100, 0, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
906709_13_item7_p17_s2
906709_12_item7_p8_s3
We expect the clinical development of our proprietary drug candidates including NKTR-102, NKTR-061, NKTR-181, and NKTR-192 will continue to require significant investments in order to advance through the clinic with the objective of entering into a collaboration partnership or obtaining regulatory approval.
We expect the clinical development of our proprietary drug candidates including etirinotecan pegol, Amikacin Inhale, NKTR-181, and NKTR-192 will require significant investment in order to continue to advance in clinical development with the objective of entering into a collaboration partnership or obtaining regulatory ...
2
[ "<tag1>", "We", "expect", "the", "clinical", "development", "of", "our", "proprietary", "drug", "candidates", "including", "NKTR-102", ",", "NKTR-061", ",", "NKTR-181", ",", "and", "NKTR-192", "will", "continue", "to", "require", "significant", "investments", "in"...
[ "We", "expect", "the", "clinical", "development", "of", "our", "proprietary", "drug", "candidates", "including", "NKTR-102", ",", "NKTR-061", ",", "NKTR-181", ",", "and", "NKTR-192", "will", "continue", "to", "require", "significant", "investments", "in", "order",...
[ "We", "expect", "the", "clinical", "development", "of", "our", "proprietary", "drug", "candidates", "including", "etirinotecan", "pegol", ",", "Amikacin", "Inhale", ",", "NKTR-181", ",", "and", "NKTR-192", "will", "require", "significant", "investment", "in", "ord...
[]
[ "etirinotecan", "pegol", "Amikacin", "Inhale", "investment" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
906709_13_item7_p43_s2
906709_12_item7_p8_s3
We expect the clinical development of our proprietary drug candidates including NKTR-102, NKTR-061, NKTR-181, and NKTR-192 will continue to require significant investments in order to advance through the clinic with the objective of entering into a collaboration partnership or obtaining regulatory approval.
We expect the clinical development of our proprietary drug candidates including etirinotecan pegol (NKTR-102), Amikacin Inhale, NKTR-181, and NKTR-192 will require significant investment in order to continue to advance in clinical development with the objective of entering into a collaboration partnership or obtaining ...
2
[ "<tag1>", "We", "expect", "the", "clinical", "development", "of", "our", "proprietary", "drug", "candidates", "including", "NKTR-102", ",", "NKTR-061", ",", "NKTR-181", ",", "and", "NKTR-192", "will", "continue", "to", "require", "significant", "investments", "in"...
[ "We", "expect", "the", "clinical", "development", "of", "our", "proprietary", "drug", "candidates", "including", "NKTR-102", ",", "NKTR-061", ",", "NKTR-181", ",", "and", "NKTR-192", "will", "continue", "to", "require", "significant", "investments", "in", "order",...
[ "We", "expect", "the", "clinical", "development", "of", "our", "proprietary", "drug", "candidates", "including", "etirinotecan", "pegol", "(", "NKTR-102", ")", ",", "Amikacin", "Inhale", ",", "NKTR-181", ",", "and", "NKTR-192", "will", "require", "significant", ...
[]
[ "etirinotecan", "pegol", "Amikacin", "Inhale", "investment" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
906709_14_item7_p18_s2
906709_13_item7_p17_s1
As of December 31, 2012, we had at least twelve months of working capital to fund our current business plans.
Key Developments and Trends in Liquidity and Capital Resources As of December 31, 2013, we estimated that we had at least twelve months of working capital to fund our current business plans.
2
[ "<tag1>", "As", "of", "December", "31", ",", "2012", ",", "we", "had", "at", "least", "twelve", "months", "of", "working", "capital", "to", "fund", "our", "current", "business", "plans", ".", "<tag2>", "Key", "Developments", "and", "Trends", "in", "Liquidi...
[ "As", "of", "December", "31", ",", "2012", ",", "we", "had", "at", "least", "twelve", "months", "of", "working", "capital", "to", "fund", "our", "current", "business", "plans", "." ]
[ "Key", "Developments", "and", "Trends", "in", "Liquidity", "and", "Capital", "Resources", "As", "of", "December", "31", ",", "2013", ",", "we", "estimated", "that", "we", "had", "at", "least", "twelve", "months", "of", "working", "capital", "to", "fund", "...
[]
[ "Key", "Developments", "Trends", "Liquidity", "Capital", "Resources", "estimated" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 1, 1, 0, 1, 0, 1, -100, 1, 1, 0, -100, 0, 0, -100, -100, 0, 0, 1, 0, 0, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
906709_14_item7_p37_s6
906709_13_item7_p21_s2
As described in Note 7 to our Consolidated Financial Statements, this royalty sale transaction has been recorded as a liability that amortizes over the estimated royalty payment period.
As described in Note 7 to our Consolidated Financial Statements, this royalty sale transaction has been recorded as a liability that amortizes over the estimated royalty payment period as CIMZIA and MIRCERA royalties are remitted directly to the purchaser.
2
[ "<tag1>", "As", "described", "in", "Note", "7", "to", "our", "Consolidated", "Financial", "Statements", ",", "this", "royalty", "sale", "transaction", "has", "been", "recorded", "as", "a", "liability", "that", "amortizes", "over", "the", "estimated", "royalty", ...
[ "As", "described", "in", "Note", "7", "to", "our", "Consolidated", "Financial", "Statements", ",", "this", "royalty", "sale", "transaction", "has", "been", "recorded", "as", "a", "liability", "that", "amortizes", "over", "the", "estimated", "royalty", "payment",...
[ "As", "described", "in", "Note", "7", "to", "our", "Consolidated", "Financial", "Statements", ",", "this", "royalty", "sale", "transaction", "has", "been", "recorded", "as", "a", "liability", "that", "amortizes", "over", "the", "estimated", "royalty", "payment",...
[]
[ "CIMZIA", "MIRCERA", "royalties", "remitted", "directly", "purchaser" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, 0, -100, -100, 0, 0, 0...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
906709_14_item7_p27_s0
906709_13_item7_p24_s0
Cost of goods sold increased during the year ended December 31, 2012 compared to the year ended December 31, 2011 primarily due to the $10.5 million increase in product sales in 2012.
Cost of goods sold and product gross profit increased during the year ended December 31, 2013 compared to the year ended December 31, 2012 primarily due to the $9.4 million increase in product sales in the year ended December 31, 2013 compared to the year ended December 31, 2012.
2
[ "<tag1>", "Cost", "of", "goods", "sold", "increased", "during", "the", "year", "ended", "December", "31", ",", "2012", "compared", "to", "the", "year", "ended", "December", "31", ",", "2011", "primarily", "due", "to", "the", "$", "10.5", "million", "increa...
[ "Cost", "of", "goods", "sold", "increased", "during", "the", "year", "ended", "December", "31", ",", "2012", "compared", "to", "the", "year", "ended", "December", "31", ",", "2011", "primarily", "due", "to", "the", "$", "10.5", "million", "increase", "in",...
[ "Cost", "of", "goods", "sold", "and", "product", "gross", "profit", "increased", "during", "the", "year", "ended", "December", "31", ",", "2013", "compared", "to", "the", "year", "ended", "December", "31", ",", "2012", "primarily", "due", "to", "the", "$",...
[]
[ "gross", "profit", "9.4" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, 0, -10...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
906709_14_item7_p42_s3
906709_13_item7_p40_s5
On February 24, 2012, we sold all of our rights to receive future royalty payments on CIMZIA and MIRCERA in exchange for $124.0 million.
Cash flows used in financing activities On February 24, 2012, we sold all of our rights to receive future royalty payments on CIMZIA and MIRCERA in exchange for $124.0 million.
2
[ "<tag1>", "On", "February", "24", ",", "2012", ",", "we", "sold", "all", "of", "our", "rights", "to", "receive", "future", "royalty", "payments", "on", "CIMZIA", "and", "MIRCERA", "in", "exchange", "for", "$", "124.0", "million", ".", "<tag2>", "Cash", "...
[ "On", "February", "24", ",", "2012", ",", "we", "sold", "all", "of", "our", "rights", "to", "receive", "future", "royalty", "payments", "on", "CIMZIA", "and", "MIRCERA", "in", "exchange", "for", "$", "124.0", "million", "." ]
[ "Cash", "flows", "used", "in", "financing", "activities", "On", "February", "24", ",", "2012", ",", "we", "sold", "all", "of", "our", "rights", "to", "receive", "future", "royalty", "payments", "on", "CIMZIA", "and", "MIRCERA", "in", "exchange", "for", "$"...
[]
[ "Cash", "flows", "used", "financing", "activities" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 1, 1, 1, 0, 1, 1, -100, 0, 0, 0, -100, 0, -100, 0, 0...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
906709_14_item7_p22_s6
906709_13_item7_p40_s6
As described in Note 7 to our Consolidated Financial Statements, this royalty sale transaction has been recorded as a liability that amortizes over the estimated royalty payment period as CIMZIA and MIRCERA royalties are remitted directly to the purchaser.
As described in Note 7 to our Consolidated Financial Statements, this royalty sale transaction has been recorded as a liability that amortizes over the estimated royalty payment period.
2
[ "<tag1>", "As", "described", "in", "Note", "7", "to", "our", "Consolidated", "Financial", "Statements", ",", "this", "royalty", "sale", "transaction", "has", "been", "recorded", "as", "a", "liability", "that", "amortizes", "over", "the", "estimated", "royalty", ...
[ "As", "described", "in", "Note", "7", "to", "our", "Consolidated", "Financial", "Statements", ",", "this", "royalty", "sale", "transaction", "has", "been", "recorded", "as", "a", "liability", "that", "amortizes", "over", "the", "estimated", "royalty", "payment",...
[ "As", "described", "in", "Note", "7", "to", "our", "Consolidated", "Financial", "Statements", ",", "this", "royalty", "sale", "transaction", "has", "been", "recorded", "as", "a", "liability", "that", "amortizes", "over", "the", "estimated", "royalty", "payment",...
[]
[]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
906709_14_item7_p18_s2
906709_13_item7_p43_s1
As of December 31, 2012, we had at least twelve months of working capital to fund our current business plans.
Key Developments and Trends in Liquidity and Capital Resources As of December 31, 2013, we estimated that we had at least twelve months of working capital to fund our current business plans.
2
[ "<tag1>", "As", "of", "December", "31", ",", "2012", ",", "we", "had", "at", "least", "twelve", "months", "of", "working", "capital", "to", "fund", "our", "current", "business", "plans", ".", "<tag2>", "Key", "Developments", "and", "Trends", "in", "Liquidi...
[ "As", "of", "December", "31", ",", "2012", ",", "we", "had", "at", "least", "twelve", "months", "of", "working", "capital", "to", "fund", "our", "current", "business", "plans", "." ]
[ "Key", "Developments", "and", "Trends", "in", "Liquidity", "and", "Capital", "Resources", "As", "of", "December", "31", ",", "2013", ",", "we", "estimated", "that", "we", "had", "at", "least", "twelve", "months", "of", "working", "capital", "to", "fund", "...
[]
[ "Key", "Developments", "Trends", "Liquidity", "Capital", "Resources", "estimated" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 1, 1, 0, 1, 0, 1, 0, 1, 1, 0, -100, 0, 0, -100, 0, 0, 0, 1, 0, 0, -100, 0, 0...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
906709_14_item7_p37_s5
906709_13_item7_p47_s4
Cash flows used in financing activities On February 24, 2012, we sold all of our rights to receive future royalty payments on CIMZIA and MIRCERA in exchange for $124.0 million.
On February 24, 2012, we sold all of our rights to receive future royalty payments on CIMZIA and MIRCERA in exchange for $124.0 million.
2
[ "<tag1>", "Cash", "flows", "used", "in", "financing", "activities", "On", "February", "24", ",", "2012", ",", "we", "sold", "all", "of", "our", "rights", "to", "receive", "future", "royalty", "payments", "on", "CIMZIA", "and", "MIRCERA", "in", "exchange", ...
[ "Cash", "flows", "used", "in", "financing", "activities", "On", "February", "24", ",", "2012", ",", "we", "sold", "all", "of", "our", "rights", "to", "receive", "future", "royalty", "payments", "on", "CIMZIA", "and", "MIRCERA", "in", "exchange", "for", "$"...
[ "On", "February", "24", ",", "2012", ",", "we", "sold", "all", "of", "our", "rights", "to", "receive", "future", "royalty", "payments", "on", "CIMZIA", "and", "MIRCERA", "in", "exchange", "for", "$", "124.0", "million", "." ]
[]
[]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
906709_14_item7_p45_s1
906709_13_item7_p51_s0
September 30, 2009 for the Mission Bay Facility, we will begin making non-cancelable lease payments in 2014.
Under the terms of the sublease we entered into with Pfizer Inc. on September 30, 2009 for the Mission Bay Facility, we will begin making non-cancelable lease payments in 2014.
2
[ "<tag1>", "September", "30", ",", "2009", "for", "the", "Mission", "Bay", "Facility", ",", "we", "will", "begin", "making", "non", "-", "cancelable", "lease", "payments", "in", "2014", ".", "<tag2>", "Under", "the", "terms", "of", "the", "sublease", "we", ...
[ "September", "30", ",", "2009", "for", "the", "Mission", "Bay", "Facility", ",", "we", "will", "begin", "making", "non", "-", "cancelable", "lease", "payments", "in", "2014", "." ]
[ "Under", "the", "terms", "of", "the", "sublease", "we", "entered", "into", "with", "Pfizer", "Inc.", "on", "September", "30", ",", "2009", "for", "the", "Mission", "Bay", "Facility", ",", "we", "will", "begin", "making", "non", "-", "cancelable", "lease", ...
[]
[ "terms", "sublease", "entered", "Pfizer", "Inc." ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, -100, 1, -100, -100, 1, -100, 1, -100, 0, 1, 1, 0, 0, 0, 0, -100, -100, -100, -100, -...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
906709_14_item7_p45_s3
906709_13_item7_p51_s2
Under the terms of the amendment, beginning January 1, 2012, we began making lease payments for this additional space of $40,000 per month until at least May 31, 2013.
Under the terms of the amendment, beginning January 1, 2012, we began making lease payments for this additional space.
2
[ "<tag1>", "Under", "the", "terms", "of", "the", "amendment", ",", "beginning", "January", "1", ",", "2012", ",", "we", "began", "making", "lease", "payments", "for", "this", "additional", "space", "of", "$", "40,000", "per", "month", "until", "at", "least"...
[ "Under", "the", "terms", "of", "the", "amendment", ",", "beginning", "January", "1", ",", "2012", ",", "we", "began", "making", "lease", "payments", "for", "this", "additional", "space", "of", "$", "40,000", "per", "month", "until", "at", "least", "May", ...
[ "Under", "the", "terms", "of", "the", "amendment", ",", "beginning", "January", "1", ",", "2012", ",", "we", "began", "making", "lease", "payments", "for", "this", "additional", "space", "." ]
[]
[]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
906709_14_item7_p46_s3
906709_13_item7_p51_s3
The sublease is discussed in Note 6 of Item 8.
This is further discussed in Note 6 of Item 8.
2
[ "<tag1>", "The", "sublease", "is", "discussed", "in", "Note", "6", "of", "Item", "8", ".", "<tag2>", "This", "is", "further", "discussed", "in", "Note", "6", "of", "Item", "8", ".", "<tag3>" ]
[ "The", "sublease", "is", "discussed", "in", "Note", "6", "of", "Item", "8", "." ]
[ "This", "is", "further", "discussed", "in", "Note", "6", "of", "Item", "8", "." ]
[]
[]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
906709_14_item7_p45_s4
906709_13_item7_p52_s3
This is further discussed in Note 6 of Item 8.
The sublease is discussed in Note 6 of Item 8.
2
[ "<tag1>", "This", "is", "further", "discussed", "in", "Note", "6", "of", "Item", "8", ".", "<tag2>", "The", "sublease", "is", "discussed", "in", "Note", "6", "of", "Item", "8", ".", "<tag3>" ]
[ "This", "is", "further", "discussed", "in", "Note", "6", "of", "Item", "8", "." ]
[ "The", "sublease", "is", "discussed", "in", "Note", "6", "of", "Item", "8", "." ]
[]
[ "sublease" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, 1, -100, 0, 0, -100, -100, -100, -100, -100, 0, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
906709_14_item7_p6_s0
906709_13_item7_p5_s0
On November 12, 2012, AstraZeneca announced positive top-line results from two Phase 3 efficacy and safety clinical trials and from a safety extension trial (KODIAC-04, -05, and -07).
On November 12, 2012, AstraZeneca announced positive top-line results for naloxegol from two Phase 3 efficacy and safety clinical trials and from a safety extension trial (KODIAC-04, -05, and -07).
2
[ "<tag1>", "On", "November", "12", ",", "2012", ",", "AstraZeneca", "announced", "positive", "top", "-", "line", "results", "from", "two", "Phase", "3", "efficacy", "and", "safety", "clinical", "trials", "and", "from", "a", "safety", "extension", "trial", "("...
[ "On", "November", "12", ",", "2012", ",", "AstraZeneca", "announced", "positive", "top", "-", "line", "results", "from", "two", "Phase", "3", "efficacy", "and", "safety", "clinical", "trials", "and", "from", "a", "safety", "extension", "trial", "(", "KODIAC-...
[ "On", "November", "12", ",", "2012", ",", "AstraZeneca", "announced", "positive", "top", "-", "line", "results", "for", "naloxegol", "from", "two", "Phase", "3", "efficacy", "and", "safety", "clinical", "trials", "and", "from", "a", "safety", "extension", "t...
[]
[ "naloxegol" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
906709_14_item7_p22_s5
906709_13_item7_p69_s0
In February 2012, we sold all of our rights to receive future royalty payments from sales of the CIMZIA and MIRCERA drug products marketed by UCB and Roche, respectively.
In February 2012, we sold all of our rights to receive future royalty payments on CIMZIA and MIRCERA .
2
[ "<tag1>", "In", "February", "2012", ",", "we", "sold", "all", "of", "our", "rights", "to", "receive", "future", "royalty", "payments", "from", "sales", "of", "the", "CIMZIA", "and", "MIRCERA", "drug", "products", "marketed", "by", "UCB", "and", "Roche", ",...
[ "In", "February", "2012", ",", "we", "sold", "all", "of", "our", "rights", "to", "receive", "future", "royalty", "payments", "from", "sales", "of", "the", "CIMZIA", "and", "MIRCERA", "drug", "products", "marketed", "by", "UCB", "and", "Roche", ",", "respec...
[ "In", "February", "2012", ",", "we", "sold", "all", "of", "our", "rights", "to", "receive", "future", "royalty", "payments", "on", "CIMZIA", "and", "MIRCERA", "." ]
[]
[]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
906709_15_item7_p11_s2
906709_14_item7_p12_s2
We originally developed the liquid aerosol inhalation platform and Amikacin Inhale and entered into a collaboration agreement with Bayer in August 2007 to further advance the drug candidate s development and potential commercialization.
We originally developed the liquid aerosol inhalation platform and the NKTR-061 drug candidate and entered into a collaboration agreement with Bayer to further advance the drug candidate s development and potential commercialization.
2
[ "<tag1>", "We", "originally", "developed", "the", "liquid", "aerosol", "inhalation", "platform", "and", "Amikacin", "Inhale", "and", "entered", "into", "a", "collaboration", "agreement", "with", "Bayer", "in", "August", "2007", "to", "further", "advance", "the", ...
[ "We", "originally", "developed", "the", "liquid", "aerosol", "inhalation", "platform", "and", "Amikacin", "Inhale", "and", "entered", "into", "a", "collaboration", "agreement", "with", "Bayer", "in", "August", "2007", "to", "further", "advance", "the", "drug", "...
[ "We", "originally", "developed", "the", "liquid", "aerosol", "inhalation", "platform", "and", "the", "NKTR-061", "drug", "candidate", "and", "entered", "into", "a", "collaboration", "agreement", "with", "Bayer", "to", "further", "advance", "the", "drug", "candidat...
[]
[ "NKTR-061" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, -100, -100, -100, -10...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
906709_15_item7_p33_s4
906709_14_item7_p18_s2
Key Developments and Trends in Liquidity and Capital Resources As of December 31, 2013, we estimated that we had at least twelve months of working capital to fund our current business plans.
As of December 31, 2014, we estimated that we had at least twelve months of working capital to fund our current business plans.
2
[ "<tag1>", "Key", "Developments", "and", "Trends", "in", "Liquidity", "and", "Capital", "Resources", "As", "of", "December", "31", ",", "2013", ",", "we", "estimated", "that", "we", "had", "at", "least", "twelve", "months", "of", "working", "capital", "to", ...
[ "Key", "Developments", "and", "Trends", "in", "Liquidity", "and", "Capital", "Resources", "As", "of", "December", "31", ",", "2013", ",", "we", "estimated", "that", "we", "had", "at", "least", "twelve", "months", "of", "working", "capital", "to", "fund", "...
[ "As", "of", "December", "31", ",", "2014", ",", "we", "estimated", "that", "we", "had", "at", "least", "twelve", "months", "of", "working", "capital", "to", "fund", "our", "current", "business", "plans", "." ]
[]
[]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
906709_15_item7_p13_s0
906709_14_item7_p19_s0
The indebtedness includes $125.0 million in aggregate principal amount of 12.0% senior secured notes due July 15, 2017, but excludes our long-term liability relating to the sale of future royalties under the Purchase and Sale Agreement with RPI Finance Trust.
12.0% senior secured notes due July 15, 2017, but excludes our long-term liability relating to the sale of future royalties under the Purchase and Sale Agreement with RPI Finance Trust.
2
[ "<tag1>", "The", "indebtedness", "includes", "$", "125.0", "million", "in", "aggregate", "principal", "amount", "of", "12.0", "%", "senior", "secured", "notes", "due", "July", "15", ",", "2017", ",", "but", "excludes", "our", "long", "-", "term", "liability"...
[ "The", "indebtedness", "includes", "$", "125.0", "million", "in", "aggregate", "principal", "amount", "of", "12.0", "%", "senior", "secured", "notes", "due", "July", "15", ",", "2017", ",", "but", "excludes", "our", "long", "-", "term", "liability", "relatin...
[ "12.0", "%", "senior", "secured", "notes", "due", "July", "15", ",", "2017", ",", "but", "excludes", "our", "long", "-", "term", "liability", "relating", "to", "the", "sale", "of", "future", "royalties", "under", "the", "Purchase", "and", "Sale", "Agreemen...
[]
[]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...